Hybrid Modeling of Cancer Drug Resistance Mechanisms by SAMEEN, SHEEMA
Universita` di Pisa
Dipartimento di Informatica
Dottorato di Ricerca in Informatica
Ph.D. Thesis
Hybrid Modeling of Cancer Drug Resistance
Mechanisms
Sheema Sameen
Supervisor
Prof. Roberto Barbuti
Supervisor
Paolo Milazzo
Supervisor
Antonio Cerone
April 2016

Abstract
Cancer is a multi-scale disease and its overwhelming complexity depends upon the multiple
interwind events occurring at both molecular and cellular levels, making it very difficult
for therapeutic advancements in cancer research. The resistance to cancer drugs is a
significant challenge faced by scientists nowadays. The roots of the problem reside not
only at the molecular level, due to multiple type of mutations in a single tumor, but also
at the cellular level of drug interactions with the tumor. Tumor heterogeneity is the term
used by oncologists for the involvement of multiple mutations in the development of a
tumor at the sub-cellular level. The mechanisms for tumor heterogeneity are rigorously
being explored as a reason for drug resistance in cancer patients. It is important to observe
cell interactions not only at intra-tumoral level, but it is also essential to study the drug
and tumor cell interactions at cellular level to have a complete picture of the mechanisms
underlying drug resistance.
The multi-scale nature of cancer drug resistance problem require modeling approaches
that can capture all the multiple sub-cellular and cellular interaction factors with respect to
different scales for time and space. Hybrid modeling offers a way to integrate both discrete
and continuous dynamics to overcome this challenge. This research work is focused on the
development of hybrid models to understand the drug resistance behaviors in colorectal
and lung cancers. The common thing about the two types of cancer is that they both have
different mutations at epidermal growth factor receptors (EGFRs) and they are normally
treated with anti-EGFR drugs, to which they develop resistances with the passage of time.
The acquiring of resistance is the sign of relapse in both kind of tumors.
The most challenging task in colorectal cancer research nowadays is to understand the
development of acquired resistance to anti-EGFR drugs. The key reason for this problem is
the KRAS mutations appearance after the treatment with monoclonal antibodies (moAb).
A hybrid model is proposed for the analysis of KRAS mutations behavior in colorectal
cancer with respect to moAb treatments. The colorectal tumor hybrid model is represented
as a single state automata, which shows tumor progression and evolution by means of
mathematical equations for tumor sub-populations, immune system components and drugs
for the treatment. The drug introduction is managed as a discrete step in this model.
To evaluate the drug performance on a tumor, equations for two types of tumors cells
are developed, i.e KRAS mutated and KRAS wild-type. Both tumor cell populations
were treated with a combination of moAb and chemotherapy drugs. It is observed that
even a minimal initial concentration of KRAS mutated cells before the treatment has the
ability to make the tumor refractory to the treatment. Moreover, a small population of
KRAS mutated cells has a strong influence on a large number of wild-type cells by making
them resistant to chemotherapy. Patient’s immune responses are specifically taken into
considerations and it is found that, in case of KRAS mutations, the immune strength does
not affect medication efficacy. Finally, cetuximab (moAb) and irinotecan (chemotherapy)
drugs are analyzed as first-line treatment of colorectal cancer with few KRAS mutated
cells. Results show that this combined treatment could be only effective for patients with
high immune strengths and it should not be recommended as first-line therapy for patients
with moderate immune strengths or weak immune systems because of a potential risk of
relapse, with KRAS mutant cells acquired resistance involved with them.
Lung cancer is more complicated then colorectal cancer because of acquiring of multiple
resistances to anti-EGFR drugs. The appearance of EGFR T790M and KRAS mutations
makes tumor resistant to a gefitinib and AZD9291 drugs, respectively. The hybrid model for
lung cancer consists of two non-resistant and resistant states of tumor. The non-resistant
state is treated with geftinib drug until resistance to this drug makes tumor regrowth
leading towards the resistant state. The resistant state is treated with AZD9291 drug for
recovery. In this model the complete resistant state due to KRAS mutations is ignored
because of the unavailability of parameter information and patient data. Each tumor state
is evaluated by mathematical differential equations for tumor growth and progression. The
tumor model consists of four tumor sub-population equations depending upon the type
of mutations. The drug administration in this model is also managed as a discrete step
for exact scheduling and dosages. The parameter values for the model are obtained by
experiments performed in the laboratory. The experimental data is only available for
the tumor progression along with the gefitinib drug. The model is then fine tuned for
obtaining the exact tumor growth patterns as observed in clinic, only for the gefitinib
drug. The growth rate for EGFR T790M tumor sub-population is changed to obtain the
same tumor progression patterns as observed in real patients. The growth rate of mutations
largely depends upon the immune system strength and by manipulating the growth rates
for different tumor populations, it is possible to capture the factor of immune strength of
the patient. The fine tuned model is then used to analyze the effect of AZD9291 drug
on gefitinib resistant state of the tumor. It is observed that AZD9291 could be the best
candidate for the treatment of the EGFR T790M tumor sub-population.
Hybrid modeling helps to understand the tumor drug resistance along with tumor
progression due to multiple mutations, in a more realistic way and it also provides a way
for personalized therapy by managing the drug administration in a strict pattern that
avoid the growth of resistant sub-populations as well as target other populations at the
same time. The only key to avoid relapse in cancer is the personalized therapy and the
proposed hybrid models promises to do that.
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Chapter 1
Introduction
Over the decades, many improvements have been made to elucidate the molecular mech-
anisms for cancer development and prevention but still cancer cure is a crucial question
for researchers. One of the major problems faced in cancer treatment is its resistance to
chemotherapeutics. In order to discover the mechanisms of disease progression, it is in-
evitable to first understand the complex processes of living body. Over the years various
mathematical and computational methods have been devised to decode the digital infor-
mation of human genome for studying the behavior of human body in both normal and
disease state and also for assessing the effect and dynamics of drug inside the body. In
order to quantify and asses the interactions of molecular elements in biological systems,
new scientific discipline of system biology has emerged [4, 5]. Computer scientists joined
biologists in the quest of determining the reactive nature of biological systems and as a
result many computational techniques are introduced to address the behavior of compo-
nents of biological systems, their communication and coordination with each other and
also with the environment to produce cascading biochemical reactions [6]. Hornberg and
his colleagues declared cancer as system biology disease [7]. So, in order to study the
overwhelmingly complex cancer disease, computational modeling is essential.
Commonly used approaches for the study of biological systems arise from mathematics,
in particular ordinary differential equations (ODE). ODE can be used to quantitatively
analyze biological systems and also for understanding therapeutic efficacy inside these sys-
tems by in silico study of drug dynamics. However, this deterministic modeling approach
becomes difficult to apply when the complexity of the modeled biological system increases.
Further researches indicate that biological systems are not only deterministic but they have
inherently embedded stochasticity [8]. In many cases when there is a situation of chemical
instability and there is interaction of only few entities evolving dynamically, the best rec-
ommendable solution for modeling is to use stochastic models. While for stable systems
which involve a large number of components deterministic modeling is recommendable.
Moreover, many processes governed by nature inherently work in a hybrid way comprising
of both deterministic and continuous events. The classic example in molecular biology is
the switching on and off of certain genes according to environmental conditions [9]. This
kind of behavior can be modeled as sets of ODE, and the discrete events in temperature
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rise or fall change the dynamic behavior from one set of ODE to another[10].
Modeling of biological systems is one of the most developing area in computer science
nowadays. The efforts in modeling and simulation of biological processes are mainly fo-
cused on single biological levels or scales, e.g., genomic/proteomic, cellular, tissue, organ,
whole body, behavioral, and population. There is a need to seamlessly integrate the models
from microscales to macroscales. Such multiscale models are necessary to produce quanti-
tative and predictive models of complex biological behaviors such as cancer. At the same
time, developing the abstractions to integrate between scales will lead to a much deeper
understanding of the universal or generic features of biological phenomena.
Complexity of cancer resides on the multiscale nature of the disease. In the era of the
human genome project, scientists thought that genetic mutation information could be the
answer to the quest of cancer therapy. However, as the time passed it has become clear that
genetics is not the only governing factor for cancer initiation. The involvement of genetic
and biochemical pathways, signal transduction networks and cellular interactions made it
more and more difficult to understand the mechanism of cancer progression. Zooming into
the biological system for cancer evaluation proves the involvement of multiple molecular
systems and similarly when we zoom out to get the overall picture there is the participation
of many cellular processes to the pathogenicity of the disease. Hence, cancer is termed as
system biology disease because in order to fully understand cancer disease all of the scales
of biological information ranging from molecular to cellular and then cellular to organism
must be taken into consideration [11].
Hybrid modeling is a key for the multiscale modeling of biological systems by integrating
discrete and continuous processes going inside the organism. The dynamic and complex
nature of the biological systems can be captured by a hybrid modeling approach. In
cancer therapy it is long awaited by the physicians to not only see the impact of drug on
the overall tumor growth at cellular level but also peek through at the molecular scale
for the mutational burden carried in each tumor and response of these mutations to the
drug at the same time. Hybrid modeling seems promising to combine both continuous
and discrete events in cancer therapy, by taking drug administration as a discrete event
and tumor growth as a continuous process. The mathematical modeling helps to observe
the continuous processes of tumor growth with respect to mutation populations. Hence,
hybrid modeling technique help us to develop a model to capture cancer progression and
therapy at a multiscale viewpoint to help elucidate personalized treatment procedures for
this disease.
1.1 Motivation
Drug resistance is major impediment in cancer research. There are two types of cancer drug
resistances: intrinsic or acquired. The presence of resistant cells before the start of any
therapy indicates the occurrence of intrinsic resistance, while the activation of resistance
after the start of therapy is known as acquired resistance to the drugs [12, 13, 14, 15].
There is another recently recognized explanation for the appearance of resistance to cancer
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drugs and that is termed as tumor heterogeneity. It explains that tumor is comprised of
multiple mutated cell populations including initially unrecognized small number of resistant
cells, which then grows in number unnoticed. In the meanwhile, target specific drug kills
non-resistant cells without having any effect on resistant cells until the state of complete
resistance is acquired [16, 17, 18]. Genetic variations have high tendency to influence
the efficacy and ineffectiveness of a drug inside human body. Small therapeutic index
for cancer treatment drugs increases the urge to study pharmacogenetic associations for
cancer therapy. Nowadays cancer therapy is a personalized treatment because of difference
in mutation burden of every patient For example, in case of colorectal cancer the cetuximab
drug kills EGFR mutated tumor cells but KRAS mutated cells show no response to the drug
so different proportions of both mutations in colorectal tumors pose different behaviors for
same drug.
Various biological models have been devised to help physicians in the treatment of
different diseases but growing mortality rate due to cancer, show dire need for computer
scientists and biologists to work together in understanding the pathological behavior of
disease. Hybrid modeling is an approach recently been employed by computer scientists
for better understanding biological systems. Due to the dynamic and complex nature of
biological systems it is suitable to model them by using various deterministic and stochastic
approaches together. This research aims to provide a hybrid modeling approach for the
analysis of drug resistance mechanisms in cancer. To date there is no cancer hybrid model
available which analyze the drug resistance mechanisms in tumors along with assessing
the immune strength role on tumor growth. The aim of this research is to incorporate
the cellular processes of tumor growth, drug dynamics and immune response to study the
drug resistance by the tumor at molecular level. Two clinical case studies of lung and
colorectal tumors regarding drug resistance in cancer therapy are analyzed by utilizing a
hybrid modeling approach.
1.2 Hybrid modeling framework for the personalized
therapy of cancer
A generalized hybrid modeling framework for the solution of emerging issues in cancer
therapy has been proposed (Fig:1.1). This framework is adopted for exploring the reasons
for drug resistance mechanisms in colorectal and lung cancer in this thesis.
Hybrid models have two components: continuous and discrete. Modeling cancer by
using hybrid modeling approach makes it possible to study various aspects of the disease
including tumor progression, influence of immune system and the therapeutic procedure,
altogether. The tumor progression and immune system interactions with tumor is a con-
tinuous process, while the drug administration is a discrete step. So, the hybrid model
for cancer can take two kinds of input parameters, the continuous parameters regarding
tumor progression and immune system strength, and the discrete parameter of therapeu-
tic strategy. The tumor cells and immune system evolve in a continuous manner so they
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are represented as ordinary differential equations. The therapeutic strategy works as drug
control unit and it manages drug administration on discrete time steps.
Tumor 
Growth 
Immune System 
Response 
Therapeutic 
Strategy 
Hybrid Model for Personalized Therapy 
Solver 
Tumor Growth Patterns 
Complete 
Response 
Partial 
Response 
No 
Response 
Figure 1.1: Hybrid Modeling Framework for Personalized Therapy of Cancer
The hybrid model is then developed by utilizing both continuous and discrete input
information. The tumor cells and immune system cells evolve as continuous functions,
while drugs are administered at certain discrete levels. In order to analyze the impact of
therapeutic control as discrete step on the continuously evolving tumor and immune system
cells, the hybrid modeling is the answer. The hybrid model development phase is discussed
in detail in chapter 3 and 4. Various solvers can be used for implementing the hybrid model
e.g. Mathematica, Matlab, Octave etc. In this research work Octave version 3.6.1 is used
for the implementation of hybrid models. The implementation phase is discussed in detail
in chapter 5. The output of the solver is obtained in the form of graphical illustrations of
tumor growth patterns with respect to the therapy. The results obtained can be categorized
into three ways: one, in which tumor shows complete response to the therapy by rapid or
gradual decline in number of tumor cells until the complete removal of tumor cells. Second,
in which tumor shows partial response to the therapy with some decline in number but
not the complete removal of the cells. The tumor maintains a specific amount of cells
throughout therapeutic procedure. Third, no response to the therapy as sign of complete
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failure of treatment. The output with partial response or no response results are then
analyzed by different therapies or with different drug administration schedules to obtain
the required results.
The proposed framework can provide a way towards the personalized therapy of cancer
by solving various other kind of cancer issues related to tumor heterogeneity and cancer
stem cells by hybrid modeling.
1.3 Contributions
Nonlinear hybrid models are constructed to describe the drug resistance mechanisms in
colorectal and lung cancers. The progression of the tumor during the treatment and ap-
pearance of resistance is thoroughly studied to obtain the following results:
First, the models are validated with clinical data obtained from both wet lab experi-
ments and already published data from literature. The wet lab experimental data is used
for the understanding of the lung cancer case study while for colorectal cancer previously
published data is used. The overall tumor progression rate is determined by taking into ac-
count the individual mutation population for each tumor. Effect of drug on each population
also governs the growth pattern of the tumor. Immune strength is also taken into account
as a factor of patient variability in treatment procedures and also helps to reproduce the
accurate patient populations for the analysis.
Second, the models handle various critical aspects such as tumor proliferation rate
with respect to treatment, tumor dynamics with respect to each mutation population and
tumor growth with respect to different drug administration schedules. The impact of drug
on overall tumor along with the individual mutation population and the ratios of resistant
VS non-resistant populations provides the global picture of resistance mechanism taking
place at both molecular and cellular levels.
Third, the results are obtained to deeply understand the resistant mutations and their
behaviors with respect to specific drugs. Patient specific treatment schedules and possible
responses for the drugs are highlighted.
Fourth, the role of immune system is also taken into account to obtain unique patient
specific simulation results. Possibility of immunotherapy as future treatment options is
also discussed briefly according to model results.
Fifth, a computational framework is proposed for identifying patient-specific drug ad-
ministration schedules with respect to mutation status for postponing the potential cancer
relapse. Personalized model parameters are obtained for each patient by fitting clinical
data and impact of other drugs is obtained by using the same parameters to obtain realis-
tic results.
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1.4 Structure of the Thesis
Chapter 2: Provides quick review of biological modeling approaches. The formalisms
developed to model biological systems including differential equations, boolean networks,
bayesian networks, Petri nets, process algebras and hybrid systems are briefly reviewed to
have overall knowledge about formal modeling in biological systems.
Hybrid models in biology and specifically for cancer are also extensively discussed.
Cancer hybrid models are distributed into four classes according to their biological action
plan e.g, tumor growth and metastasis, drug-tumor interactions, tumor-immune system
interaction and tumor-drug resistance mechanisms.
Two types of hybrid modeling formalisms: hybrid automata and hybrid Petri nets
are defined in both formal and informal ways along with examples. The similarities and
comparison of these formalisms are explained and finally, a Justification has been made for
choosing hybrid automata over hybrid Petri nets for modeling of drug resistance in cancer.
Chapter 3: A hybrid model designed for the study of drug resistance mechanism in col-
orectal cancer is described in detail. In the hybrid model, the tumor and drug populations
are modeled as mathematical non-linear ordinary differential equations and the therapeutic
drugs introduction to the system is modeled as discrete step. Hybrid automata with clocks
are used to model this phenomenon, in which drug scheduling and administration is mon-
itored using clocks. The mathematical model not only comprise of tumor equations but
it also takes into account of all components of immune system involved in tumor growth.
The effect of monoclonal antibody (moAb)therapy and chemotherapy in combination is
evaluated on KRAS mutated or wild-type tumor populations.
Chapter 4: Application of hybrid modeling in lung cancer case study is explained in
detail. The lung tumor is modeled as a two state hybrid automaton as non-resistant or
resistant tumor states. Lung tumor undergoes various drug resistance mechanisms related
to each type of mutation and drug. The gefitinib and AZD9291 drug resistances are
evaluated in lung tumor comprising of four tumor sub-populations. The relation of immune
system and tumor growth factors for each sub-population is evaluated. The efficacy of
AZD9291 drug is calculated by using clinically evaluated parameters for lung tumors.
Chapter 5: Implementation of proposed hybrid models is explained in detail.
Chapter 6: Conclusion and possible ideas for the extension of proposed models as future
work are briefly described.
1.5 Published material
The part of thesis related to mathematical model of colorectal cancer has been partially
published in [19],
Sameen, Sheema, et al. A Mathematical Model for Assessing KRAS Mutation Effect on
Monoclonal Antibody Treatment of Colorectal Cancer. Software Engineering and Formal
Methods. Springer International Publishing, 2014. 243-258.
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The complete mathematical model for colorectal cancer has been published in the Jour-
nal of Theoretical Biology [20].
Sameen, Sheema, et al. ”Mathematical modeling of drug resistance due to KRAS
mutation in colorectal cancer.” Journal of theoretical biology 389 (2016): 263-273.
The paper related to the part of thesis about lung cancer model is in preparation phase
for the publication.
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Chapter 2
Background
2.1 Modeling Formalisms in Biology
Computational modeling and analysis methods are playing a vital role in understanding the
overwhelmingly complex dynamics of biological systems. In last few years huge progress is
observed in the development of various mathematical and computational models varying
from qualitative to quantitative behaviors of biological systems. The modeling formalisms
are chosen according to the biological problem or on the modeling requirements.
Biological models can be basically divided into three broader categories: discrete mod-
els,continuum models and hybrid models.
Discrete models can represent individual cells in space and time. Each cell update its
internal state according to a predefined set of biological rules. This approach is very helpful
in studying cell-cell interactions and cell proliferation. Both lattice-based and lattice free
methods are used by the discrete models. The computational complexity of such models
increases with the increase in number of cells in study and hence limits the size of the
tumor to be modeled.
Continuum models are used to study continuous behavior by utilizing differential equa-
tions. This gives global picture of the biological system instead of focusing on individual
discrete events of cells. Such kind of models are ideal for studying the tumor growth and
progression with respect to the genetic and cellular characteristics. Although larger spatial
and temporal scales are easier model by continuum approach but it often fails to capture
details of cell-level behavior.
Hybrid models integrate both discrete and continuous modeling approaches. They
perfectly combine the advantages from both modeling practices and limits their draw-
backs. The discrete part is modeled computationally while continuous part is captured
mathematically. Hence provide the extensive multi-scale view for the biological processes.
Hybrid models are powerful in a way that by integrating discrete and continuous modeling
techniques they are able to incorporate the subcellular, cellular and tissue scales of the
living systems. Hybrid modelling is a key to investigate biological processes at multi-scale
level[21].
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Many formalisms have been used to model biological systems [22]. The two main cate-
gories for formal modeling approaches depends upon the property of biological system to
be studied. The biological system can either be studied by taking into consideration of
qualitative aspect or by quantitative properties of a system. Fisher and Henzinger catego-
rized the biological models into computational versus mathematical [23] and Bonzanni et
al. phrase it as operational versus denotational models [24]. Denotational or mathemat-
ical models calculate mathematical relationships between quantities and change in their
behavior with time. Operational models are generally qualitative in nature and provide
high abstraction level.
Different formalisms are proposed to study qualitative and quantitative aspects of bi-
ological systems. The qualitative aspect reflect on the state dependent properties e.g.
reachability of states. On the contrary, the quantitative aspects are related to time and
probability dependent properties e.g. time or probability required to reach a certain state.
The tumor dynamics is mostly studied by quantitative means in order to calculate the time
for tumor progression or relapse of the disease. Quantitative aspects are often represented
as stochastic formal methods. Biological processes are intrinsically stochastic, this prop-
erty of biological systems makes stochastic modeling a fundamental approach of research
[25]. Most famous stochastic formulation is provided by Gillispie, in which the chemical
kinetics of biochemical reactions is based upon the interactions among the molecules [26].
The main formalisms developed to model biological systems including, differential equa-
tions, boolean networks, bayesian networks, Petri Nets, process algebras and hybrid Sys-
tems are briefly discussed below:
Differential equations
Mathematical modeling is considered to have a significant role in the study of biological
systems. They are essential for providing insight for precise theoretical arguments about
the factors affecting system under study and they can also be utilized for making predictions
about future evolution of the system under observation. Differential equations are mostly
used for dynamical systems modeling. They measure the rate of change of continuous
variables. Ordinary differential equations (ODEs) have been used extensively in systems
biology for modelling biochemical pathways, regulatory networks,gene expression processes
and many more. The first model for metabolic dynamics in Saccharomyces cerevisiae was
made using differential equation [27]. The Tyson et al. described the dynamics of regulatory
and signalling pathways in detail by non-linear differential equations [28]. The metabolic
processes of carbon metabolism of Escherichia coli is modeled using ordinary differential
equations by Chassagnole [29]. The idea of modeling gene expression by mathematical
equations is given by Chen et al.[30].
The use of mathematical models has also some limitations: for example, such models
are often based on differential equations describing how the concentration of a substance
in a solution changes over time. Differential equations are continuous and deterministic.
This makes them suitable to model solutions with substances in high concentrations, and
to analyse such models efficiently by means of numerical integration. However, differential
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equations are not suitable to model systems with components which occur in small numbers
and whose behaviour could be determined by choices between alternatives associated with
probabilities. Another limitation of differential equation modelling is that they require a
lot of experimental data and insight into reactions in order to build realistic models.
Boolean networks
Kauffman introduced boolean networks to model gene regulatory networks [31]. A boolean
network consists of a discrete set of variables. Each variables is assigned with a function
that takes inputs from variables and produces output which determines the state of the
variable. In a genetic network, boolean variables that represent active and inactive states.
The state of each gene is calculated by a function at each time step and a global state is
achieved by combining states of all of the genes. Rene Thomas has introduced a kinetic
logic to model biological regulatory networks based upon the boolean network approach.
Kinetic logic is a multivalued logic, which allows us to approximate the sigmoid nature of
biological entities more closely [32].
Boolean modeling for system biology has a very big limitation that, it only deals with
two levels, i.e., 0 and 1. Whereas biological systems are very complex as they contain a
lot of biological entities which demands more than two levels for capturing their dynamics
more accurately. For large biological networks it is almost impossible to explore all possible
states.
Despite of their strong limitation for biological modeling boolean models are still being
used for exploring some interesting processes in biology [33]. Some recent examples for
boolean modeling of biological systems include, boolean model for yeast apoptosis helps
to understand the apoptotic processes in yeast and humans [34], a cardiac gene regulatory
network is identified using a boolean model [35], another model predicts mutant phenotypes
of fission yeast [36].
Bayesian networks
Bayesian networks (BNs) are also known as belief networks [37]. They are probabilistic
graphs in which the nodes represent variables and the conditional dependencies on the
variables are represented by edges between variables. The probabilistic dependencies are
often calculated by statistical and computational methods. There are learning methods to
infer both structure and probability parameters which makes Bayesian networks suitable
for biological applications. They have been used for modeling gene regulatory [38, 39] and
signaling networks [40]. The drawback of Bayesian networks is that they do not model
feedback loop, which makes them inappropriate for biological systems. The extension in
the form of dynamic Bayesian networks is proposed to overcome this problem [41].
Petri nets
Petri nets are bipartite graphs having two types of nodes, places and transitions. These
nodes are connected by directed arcs. Petri nets are non-deterministic and good in design to
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model concurrent events. The capturing of concurrent events and the intuitive graphical
notations are considered main advantages of Petri nets. Biochemical networks can be
suitably modeled using Petri nets by representing gene or proteins as places in Petri net
and biochemical reactions can be represented as transitions and a transition is fired to
execute a reaction.
Reddy with his co-workers was the first one to report the application of Petri nets in the
biological modeling of metabolic pathways [42]. A lot of contributions in system biology are
based on Petri nets including the modeling of reaction-diffusion systems [43], multi-scale
modeling of ion channels, the modeling of bacterial regulatory networks [44], analysis of
metabolic systems [45], signal transduction pathway analysis [46]. Recent tools designed for
the analysis of biochemical pathways and networks are STEPP [47] and Snoopy [48]. The
main disadvantage of Petri nets is that they become very large to handle with relatively
big systems and also it is not possible to treat separately every single components of a
model.
Process algebras
Process algebras is an umbrella term for formal languages that model concurrent systems.
They usually consist of a set of process primitives, operators for sequential and parallel
composition of processes, and communication channels.
One of the first process algebra is the Calculus of Communicating Systems (CCS)
developed by Milner [49]. The CCS is extended into the pi − calculus. The pi-calculus
[50] is a process algebra originally developed for describing concurrent processes, that are
able to communicate by using channels. The key feature of the calculus is its ability to
represent mobility, i.e. the movement of an agent to a different location in a virtual space
of processes.
Bio-PEPA [51, 52, 53] has been developed for modeling biochemical networks, it allows
to express stoichiometric coefficients and general kinetic laws in reactions. The abstraction
of the behavior of complex systems with missing low-level details becomes easier when
general kinetic laws are known. It also allows the use of different compartments of different
sizes.
Brane Calculi [54] is proposed by Cardelli for the modeling of interactions of biolog-
ical membranes. Another calculus inspired by the pi-calculus and Mobile Ambients give
rise a new calculus which deals with the compartment is known as BioAmbients [55].
Beta Binders [56] models biological membranes, by enclosing pi-calculus processes inside
membranes. In that way the communication with the external environment is possible
through specific interfaces. Another interesting formalism for protein-protein interactions
is κ−calculus [57]. BlenX [58] is proposed to simulate the evolution of biological networks.
Other formalisms
Recent advances in formalisms for biological entities arise by the idea of membrane com-
puting. Paun was the first one to propose that idea as membrane systems [59]. Membrane
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systems (or P systems) is a computational formalism designed to represent biochemical
reactions inside membranes as evolution rules from multisets of objects present on each
membrane [60]. Various extensions of P systems have been introduced to model various
aspects of biological systems, they include: metabolic P systems derived for modeling the
evolution of biochemical processes deterministically [61], ecological P systems extension
is based upon the probabilistic approach of P systems to describe the behavior of meta-
populations [62, 63], multi-environment P systems applied to the modelling of ecosystems
[64, 65], tissue like P system [66, 67] and lattice population P systems [68, 69].
Similarly, the Calculus of Looping Sequences (CLS) proposed by Barbuti et al. is a
formalism focused on the evolution of a biological system, which is represented by means
of rewrite rules [70, 71, 72]. This rewrite rule based approach is ideal for modeling complex
biochemical reactions.
CLS allows an easy description of microbiological systems and their evolution. It allows
modeling membranes, which are first-class elements of the calculus and, thus, can evolve
and take part in reactions. Some extensions of the calculus have been developed. Stochastic
CLS [73] allows the description of quantitative aspects of the modeled systems, such as the
frequency of chemical reactions. CLS with links (LCLS) allows for the description of protein
interaction at the domain level [74].
The P systems and Calculus of Looping Sequences are suitable for modeling the complex
behaviors of tumor growth, progression and its behavior on the use of chemotherapeutics.
Deterministic-stochastic hybrid modeling
To date a variety of hybrid models have been developed in system biology. One of the
first kind of hybrid models were based upon the idea of mixing stochastic and determin-
istic approaches to obtain more efficient simulations of systems. For example, the Tau
leap method has been proposed by Gillespie [75, 76]. Similarly, Haseltine and Rawlings
[77] proposed efficient hybrid simulations by separating systems into the slow and fast re-
actions. In another approach by Rao and Arkin [78] some reactions are simulated using
Gillespie algorithm explicitly while the others by random variables distributed according
to the probability density functions at quasi-stationary state. Salis and Kaznessis [79]
came up with a method in which they described parameters to define number of reactions
occurring in a time step. A Stochastic Concurrent Constraint Programming (SCCP) alge-
bra proposed by Bortolussi and Policriti [80] provide semantics by combining discrete and
continuous steps hybrid automata. A hybrid technique is established for ODE with the
Runge-Kutta numerical approximation method [81]. Stochastic calculus technique, hybrid
method developed by integrating ODEs and stochastic simulations [82, 83]. The HYPE
process algebra is also introduced in to hybrid modeling [84]. Finally in 2012, hybrid simu-
lation method is introduced for systems described in Calculus of Wrapped Compartments
(CWC)[85].CWC was developed to model biological systems, which is simplification of
CLS. That approach was very good to analyze various biological processes but it was not
much efficient according to complexity of large biological systems.
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2.2 Cancer hybrid models
Cancer modeling is being utilized from decades to understand all the molecular processes
taking place in the formation of a tumor. Until now, many key processes involved in
cancer are modeled by different approaches. These include modeling of tumor growth and
progression [86, 87], tumor angiogenesis [88, 89], tumor metastasis [90, 91, 92], intracellular
pathways involved in tumor initiation [93, 94], drug dynamics [95, 96] and many more [97].
All of these models can be categorized as discrete or continuous models [98], which means
that all of these models have limitations related to their respective modeling approaches.
The cancer hybrid models can be categorized into four main groups according to bi-
ological processes; Tumor growth and metastasis hybrid models, drug-tumor interaction
hybrid models, tumor-immune system interaction hybrid models and tumor-drug resistance
hybrid models.
2.2.1 Tumor growth and metastasis hybrid models
Recently, cancer modeling is more focused towards hybrid modeling approaches. Rejniak
and Anderson has categorized hybrid models of tumor growth into on-lattice models and off-
lattice models [99]. On-lattice models mainly use cellular automata. Gerlee and Anderson
et al., produced hybrid cellular automata models to study the solid tumor growth and
also to configure the impact of environment on tumor growth [100, 101]. These on-lattice
models has gained much consideration among scientists because of their ability to observe
tumor growth and invasion by hybrid discrete-continuum method. It suggests that tumor
morphology variation depends upon tumor micro-environment conditions. But the on-
lattice models has certain limitations because of the use of rule-based cellular automata
on square lattice. In the work done by Gerlee and Anderson the cell motility factor is not
captured well because of that limitation. Off-lattice models can easily overcome such type
of limitations as they give more realistic representation of cell spatial locations because
they are not required to uniformly spaced on a fixed grid. Hence, an off-lattice model of
cell motility with detailed forces describing cell-cell and cell-ECM interactions can provide
more detailed information of tumor growth and progression[102]. These hybrid modelling
formalisms only provide the representation of tumor growth mechanisms because they are
specifically spatio-temporal in nature but they do not give any explanation about the
molecular or genetic burden underlying in tumor growth. Neither they explain the cancer
drugs behavior with respect to tumor growth dynamics.
Agent based modelling is also a discrete-based hybrid modeling approach. It not only
allows to study the cell populations but it also gives insight within each individual cell
[103]. This kind of modelling is suitable for the cancer metastasis as it provides more
phenotypic information and helps to generate 3D representations.
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2.2.2 Drug-tumor hybrid models
Drug dynamics is extensively studied for the impact on tumor growth. However, study-
ing both drug and tumors dynamics together as hybrid systems is not a very old idea.
Wang and his colleagues recently published a very interesting work which combines drug
pharmacokinetic-pharmacodynamic (PK-PD) with the agent based model (ABM)[104].
Both of these are widely applied in cancer research as PK-PD explain about the drug
efficacy and resistance in cancer while ABM are extensively studied for predicting tumor
growth and progression. This seems a promising hybrid model for explaining the drug
dynamics and tumor response in both time and scale but it does not give any clue about
the effect of mutation on the tumor progression. There are some other models published
in previous years for explaining the effect of chemotherapeutic drugs on solid tumors, e.g,
Powathil et al., studied the effect of cell-cycle heterogeneity within each cell of tumor and
response of tumor to the chemotherapy. The cell cycle heterogeneity among tumor cells
has large impact on the response to the drugs. This is again studied by cellular automata
giving more phenotypic information [105].
2.2.3 Tumor-immune system hybrid models
Human immune strength plays a decisive role in the success of all cancer therapies. Taking
consideration of immune responses in tumor modelling is being done from last decade but
initially the immune response was thought to be limited to only cytotoxic T lymphocytes.
With the passage of time other components of immune system are also being considered
gradually for complete immune strength assessment.
Tumor-immune system interactions are studied by Mallet and De Pillis by presenting
hybrid cellular automata with partial differential equation model. This model explicates
the role of immune system in tumor suppression or progression [106]. Kim and Lee investi-
gated the interactions of cytotoxic T lymphocyte cells with tumor to predict the impact of
immunotherapy as future cancer treatment. The tumor-immune interactions are observed
using an agent-based model (ABM) for tumor and dynamics in the lymph node by us-
ing a system of delay differential equations (DDEs). Model revealed conditions for rapid
tumor destruction by immunotherapy [107]. A model of the immune response to chronic
myelogenous leukemia in post-transplantation dynamics using time delays is proposed by
Niculescu and her colleagues [108]. This model considers that immune strength only relies
upon cytotoxic T lymphocyte. But there are many other immune cell populations includ-
ing natural killer cells, helper T cells, lymphocytes etc. that are needed to be taken into
account. Nanda et al., developed a discrete-continuous model for the B cell chronic lym-
phocytic leukemia (B-CLL). B-CLL tumors have extreme heterogeneity depending upon
the immune strengths of the patients, which makes each patient respond differently to
the same therapy. This model includes almost all essential immune system components of
the body involved in cancer progression e.g. natural killer cells, cytotoxic T lymphocytes
and helper T cells. Influence of immune systems on each patient is thoroughly examined
and its impact on disease progression is explored to have better personalized treatments
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in future[109]. Another model proposed by De Pillis et al., studies the effect of regulatory
T-cells on renal cell carcinoma treated with immunotherapy [110].
2.2.4 Tumor-drug resistance hybrid models
Drug resistance is a key hurdle in cancer therapy since it leads to a relapse of the disease
after some time in which the therapy was successfully administered. There is no single
reason for drug resistance hence it is encouraged to find the solution in pharmacogenetics.
There are very few hybrid models which allow for analyzing drug-resistance phenomena.
Almost all these models include drug resistance as a measure of heterogeneity among cells in
tumor tissue. The heterogenous nature of tumor mass is currently being studied as a reason
for drug resistance in tumor therapeutic procedures. Each cell in a tumor is considered
to be unique because of its biochemical interaction and own internal cellular pathways
contributing towards major changes at cellular levels. These individual characteristics of
each cell makes tumor a heterogenous mass of cells. Tumor heterogeneity is considered to
be a reason for chemotherapy resistance in cancers. This is first time studied by hybrid
modelling in a research by Chaplain and Powathil in year 2015 [111].
2.3 Hybrid modeling
All of the classes of hybrid models described in previous section deals with a specific aspect
of cancer. Small therapeutic index for cancer treatment drugs increases the urge to study
all of these aspects of cancer research to find a way towards personalized medicine. In this
work, it is tried to capture all of the tumor, drug and immune system interactions for the
solution of drug resistance problem. It is possible to address all these characteristics by
incorporating hybrid modelling techniques. Hybrid system is described as the system com-
prised of discrete and continuous events dynamically. The interplay between discrete and
continuous behaviors of several processes allows a system to flow and jump simultaneously.
Biological processes mainly work as hybrid models as the discrete and continuous functions
occur together at the same time. The complete understanding of biological phenomena is
dependent upon retrieving the global picture of the molecular processes that takes place
together in cell and nowadays this task has become easier by the development of various
hybrid modeling formalisms and their applicability in the field of system biology. There can
be various formalisms to deal with hybrid modeling but the formalisms that are frequently
explored in the field of system biology include hybrid automata and hybrid Petri nets.
In this section we will recall the definition of hybrid automata and hybrid Petri nets.
We will start with timed automata that will be useful to define hybrid automata.
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2.3.1 Timed Automata
Informal Definition
A timed automaton [112] is essentially a finite automaton with real-valued variables rep-
resenting the logical clocks in the system. The clocks are initialized with zero at the start
of the execution of the system and then their value increments along with the passing
time. Clock constraints are guards over clocks and a transition occurs when the clock
value satisfies the guard on the edge. Alur et al., has discussed in detail the theory of time
automata.
Formal Definition
Formally, a timed automaton T is a tuple,
T = (V, ∑, V0 ,C,E, Inv)
Where:
• V is a set of states
• V0 ∈ V is the set of initial states
•
∑
is a finite alphabet of actions
• C is a finite set of clocks, and
• E ⊆ V × B(C) × ∑ × 2C × V is a set of edges, in which B(C) is the constraint over
clocks.
• Inv: V → B(C) assigns clock constraint to states
An edge V
g,a,S−−−→ V ′, represents a transition from V to V ′ on input symbol a. S is
a set of clocks to be reset with the transition while the g is a guard over C. A timed
automata is labeled with finite set of clock variables, called clocks. Clocks are different
from usual variables, as their access is limited: clocks may only be inspected, and reset to
zero. After every transition clocks are reset to zero after which they start increasing their
value implicitly as time progresses. All clocks proceed at rate one, i.e., after the elapse of
d time units, all clocks advance by d. Clocks can intuitively be considered as stopwatches
that can be started and checked independently of one another. Conditions on the values of
the clocks are used as enabling conditions (i.e., guards) of actions: only if the condition is
fulfilled the action is enabled and capable of being taken; otherwise, the action is disabled.
Conditions which depend on clock values are called clock constraints. In timed automata
all clocks change at the same rate.
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2.3.2 Hybrid Automata
Informal Definition
A very informal and commonly used definition of hybrid systems says that a hybrid system
is a system with combined discrete and continuous behaviors.
A hybrid automaton can also be defined as a finite-state automaton connected with the
collection of dynamical systems with continuously evolving variables. The discrete events
are edges of the automaton that allows the automaton to switch from one dynamical state
to another. The continuous evolution is modeled by differential equations. In each mode of
automaton the evolution laws for continuous variables may change but the set of continuous
variables remains the same.
A hybrid automaton can be also described as an extension of timed automata. In timed
automata the clocks change continuously with the passing time and they all behave in same
way but in hybrid automata it is possible to define how each variable changes with time
by means of ordinary differential equations. In other words, a timed automata is defined
as a hybrid automata when each c ∈ C changes according to dc
dt
= 1.
Formal Definition
Formally, a hybrid automaton H is a tuple,
H = (V, E, X, Init, Inv, Flow, Jump)
where:
• G = (V,E) is a control graph. This is a finite labelled graph consisting of a set
of vertices V and edges E which represent control modes and control switches of a
discrete event respectively.
• X is a finite set of real valued variables represented as {x1, x2, . . . , xn}. The set of X˙
variables {x˙1, x˙2, . . . , x˙n} represent variables evolving at continuous state, while, X ′
={ x′1, x′2,. . ., x′n } represent variables at the conclusion of each discrete state.
• Init, Inv and Flow are the conditions associated with continuous evolution of the
variables at each state. In other words, Init, Inv are conditions that govern the
continuous flow of differential equations associated with each vertex v ∈ V .
– Init : X → R describes initial conditions whose free variables are from X and
which states the possible valuations for those variables at the start of each state
v.
– Inv is a formula associated with each v ∈ V , whose free variables are from
X and which calculates the possible valuations for those variables during the
continuous evolution of variables in a v.
– Flow conditions are described as differential equations, whose free variables are
from X ∪ X˙.
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• Jump is an edge labelling function that assigns to each control switch e ∈ E. It
defines the transitions values for each variable. Each jump condition jump(e) has
free variables from X ∪ X ′
Hybrid automata generalize time automata by varying clock variables with different
rates or in a dynamic way. In the hybrid automata edges are labeled with (g, α, D), Where
g ⊆ CC(C) is a set of constraint over clocks, α ⊆ Act is an action to be performed if
guards are satisfied and D ⊆ C a set of clocks. It means that a automaton can move from
x to x′, where x and x′ ∈ X, when clock constraint g holds. Besides, when moving from
state x to x′, any clock in D will be reset to zero and action α is performed.
Examples
The hybrid modeling is a well established field of research as it has many applications in
various fields of studies, including biology. The working of hybrid models is explained by
two examples, one is a very simple classic example of a thermostat stated by the father
of hybrid automata, Thomas A. Henzinger in his paper [1]. Another example is the most
recent application of hybrid modeling in cancer therapeutic research.
Thermostat: A thermostat controls the environmental temperature at desired level. In
hybrid model of a thermostat the temperature is represented by variable x. There are two
control modes for heater, off and on. The flow conditions for each mode are:
• Control mode Off: x˙ = −0.1x
• Control mode On: x˙ = 5− 0.1x
Initially the heater is on and the temperature is 20 degrees, hence, the initial temperature
is x=20. The jump condition is x ≤ 19, Which means that the heater may go on as soon
as the temperature falls below 19 degrees and go off as soon as temperature is greater than
22. The invariant condition which tells the condition for a heater to stay within Off state
is x ≥ 18. It controls that a heater in a way that, the heater must start at the latest
when temperature falls to 18 degrees. Similarly, the invariant condition for the ’On’ state
is x ≤ 22. The graphical representation of thermostat automata is given in Fig. 2.1.
x > 21
_x =  0:1x _x = 5  0:1x
x  18 x  22
x = 20
O On
x < 19
Figure 1: Thermostat automaton
1.2 Safe Semantics
The execution of a hybrid automaton results in continuous change (ows) and
discrete change (jumps). The mixed discrete-continuous dynamics can be ab-
stracted by a fully discrete transition system.
Denition 1.2 [Labeled transition systems] A labeled transition system S con-
sists of the following components.
State space. A (possibly innite) set Q of states, and a subset Q
0
 Q of
initial states.
Transition relations. A (possibly innite) set A of labels, and for each label
a 2 A, a binary relation
a
! on the state space Q. Each triple q
a
!q
0
is
called a transition.
A subset R  Q of the state space is called a region. Given a region R and
a label a 2 A, we write post
a
(R) = fq
0
j 9q 2 R: q
a
!q
0
g for the region of a-
successors of R, and we write pre
a
(R) = fq j 9q
0
2 R: q
a
!q
0
g for the region of
a-predecessors of R. 2
For a given hybrid automaton, we dene two labeled transition systems. Both
transition systems represent discrete jumps by transitions. The timed transition
system abstracts continuous ows by transitions, retaining only information
about the source, the target, and the duration of each ow. The time-abstract
transition system abstracts also the duration of ows.
Denition 1.3 [Transition semantics of hybrid automata] The timed transition
system S
t
H
of the hybrid automatonH is the labeled transition system with the
components Q, Q
0
, A, and
a
! for each a 2 A, dened as follows.
 Dene Q;Q
0
 V  R
n
such that (v;x) 2 Q i the closed predicate
inv (v)[X := x] is true, and (v;x) 2 Q
0
i both init(v)[X := x] and
inv (v)[X := x] are true. The set Q is called the state space of H, and the
subsets of Q are called H-regions.
 A =  [R
0
.
3
Figure 2.1: Thermostat Aut maton by Heinzinger [1]
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Hybrid model for hormone therapy of prostate cancer: Liu et al. proposed a
hybrid automata model for prostate cancer cell dynamics in response to therapy [2]. The
tumor progression is monitored during the therapeutic treatment of intermittent androgen
suppression. The progression and survival of prostate cancer depends upon the levels
of androgens. The prostate tumor consist of two sub-populations of cells, the hormone
sensitive cells and castration resistant cells. Drop in androgen level considerably reduces the
rate of tumor proliferation of hormone sensitive cells but at the same time it also increases
the conversion rate of hormone sensitive cells to castration resistant cells. Intermittent
androgen suppression (IAS) was proposed to limit the duration of androgen-poor conditions
and avoid emergence of castration resistant cells. This IAS therapy switches between on-
treatment and off-treatment modes by monitoring the serum level of a tumor marker called
prostate-specific antigen (PSA). When PSA level decreases to some lower threshold limit
the androgen suppression is stopped and when PSA level increases to the upper threshold
level the androgen suppression is resumed. Hence the proposed hybrid model deals with
two states of therapy, on-treatment mode and off-treatment mode. This hybrid model
provide framework for identification of patient specific treatment schedules for avoiding
cancer relapse. It takes into account the population of HSCs, the population of CRCs, as
well as the serum androgen concentration, represented as x(t), y(t), and z(t), respectively.
In addition, it also includes the serum prostate-specific antigen (PSA) level v(t), which is
a commonly used biomarker for assessing the total population of prostate cancer cells. In
the off treatment mode of model the androgen concentration is maintained at the normal
level z0 by homeostasis, while, in the On-treatment mode the androgen is cleared at a
rate 1
τ
. The basal androgen production rate is also introduced at the rate of µz. The
effect of both mode of treatments are carefully observed with respect to growth of tumor
sub-populations. The proposed hybrid automata by Liu et al. is represented in figure 2.2.
depict the dynamical changes of proliferation rates induced
by perturbing androgen levels that are diﬃcult for previous
models (e.g. [20]) to capture. It also addresses the variabil-
ity in individual patients and is able to accurately reproduce
the datasets of diﬀerent patients.
– Second, we obtain interesting insights on CRC prolifera-
tion dynamics through analysis of the nonlinear model. Our
results support the hypothesis that the physiological level of
androgen reduce CRCs [20], while rule out other hypotheses,
for instance, CRCs proliferate at a constant rate [32].
– Third, we propose a computational framework for iden-
tifying patient-speciﬁc IAS schedules for postponing the po-
tential cancer relapse. Speciﬁcally, we obtain personalized
model parameters by ﬁtting to the clinical data in order
to characterize individual patients. We then use δ-decision
produces and bounded model checking to predict therapeu-
tic strategies.
Through this case study, we aim to highlight the oppor-
tunity for solving realistic biomedical problems using formal
methods. In particular, methods based on δ-reachability
analysis suggest a very promising direction to proceed.
Related Work. We perform parameter synthesis, which re-
quires the computation of concrete trajectories and param-
eter values. This can not be done by simply computing
an over-approximation of the forward reachable set. Con-
sequently, reachable set computation tools such as SpaceEx
[11] and Flow* [7] can not be directly used. There exists vari-
ous approaches for performing parameter synthesis through
extra reﬁnement on the reachable sets [10, 2, 12], but are
restricted to dynamics that are much simpler than the mod-
els we encounter here. On the other hand, other SMT-based
methods for hybrid systems [8, 9], which can perform param-
eter synthesis in a similar manner, mostly focus on eﬃcient
handling of complex discrete transitions but are restricted
to models with simpler continuous dynamics.
The rest of the paper is organized as follows. We de-
scribe our model in Section 2 and present preliminaries on
δ-reachability analysis in Section 3. In Section 4, we present
the biological insights we gained through this case study, as
well as the model-predicted treatment schemes for individ-
ual patients. In the ﬁnal section, we summarize the paper
and discuss future work.
2. AHYBRIDMODELOFPROSTATECAN-
CER PROGRESSION
In this section, we propose a hybrid automata based model
in order to reproduce the clinical observations [4, 5] of prostate
cancer cell dynamics in response to the IAS therapy. It is
known that the proliferation and survival of prostate cancer
cells depend on the levels of androgens, speciﬁcally testos-
terone and 5α-dihydrotestosterone (DHT). Here we consider
two distinct subpopulations of prostate cancer cells: hor-
mone sensitive cells (HSCs) and castration resistant cells
(CRCs). Androgen deprivation can lead to remarkable de-
creases of the proliferation and survival rates of HSCs, but
also up-regulates the conversion from HSCs to CRCs, which
will keep proliferating under low androgen level. The corre-
sponding hybrid automata model is shown in Figure 1.
Our model is based on previous models developed by [22,
21, 20]. It takes into account the population of HSCs, the
population of CRCs, as well as the serum androgen concen-
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Figure 1: A hybrid automaton model for prostate
cancer hormone therapy. Symbol “||” denotes the
parallel composition of the two automata.
tration, represented as x(t), y(t), and z(t), respectively. In
addition, it also includes the serum prostate-speciﬁc antigen
(PSA) level v(t), which is a commonly used biomarker for
assessing the total population of prostate cancer cells. The
model has two modes: on-treatment mode and oﬀ-treatment
mode (note that the auxiliary Mode 3 will only be used
in Section 4.2). Following [20], in the oﬀ-treatment mode
(Mode 2), the androgen concentration is maintained at the
normal level z0 by homeostasis. In the on-treatment (Mode
1), the androgen is cleared at a rate 1
τ
. Further, we also
introduce a basal androgen production rate μz, in order to
reproduce the measured basal testosterone levels in response
to androgen suppression [4, 5].
The net growth rate of x(t) equals to (prolifx − apopx −
convx)·x(t), where prolifx, apopx and convx denote the pro-
liferation, apoptosis and conversion rates, respectively. In
previous studies such as [22, 21, 20], the prolifx and apopx
were modeled using Michaelis-Menten-like (MML) functions,
in the form of Vmax + (1− Vmax) z(t)z(t)+Km , where Vmax and
Km are kinetic parameters. This approach will result in an-
drogen response curves as shown in Figure 2(a). In particu-
lar, when one decreases the androgen level starting from the
normal level, prolifx (or apopx) begins to decrease (or in-
crease) ﬁrst slowly and then fast until a suﬃciently low level
of androgen is reached. However, this is inconsistent with
the clinical observations presented in [4, 5]. The data show
that for most of the patients, androgen suppression around
normal level will induce an immediate decrease of the PSA
level, which implies an fast decrease (or increase) of prolifx
(or apopx). Therefore, instead of the MML functions, we
adopt sigmoid functions, in the form of 1
1+exp(−(z(t)−k1)·k2) ,
to model prolifx and apopx. The corresponding androgen
response curves are shown in Figure 2(b). Following [20],
we model the conversion rate, proliferation rate and the
apoptosis rate of y(t) as m1(1 − z(t)z0 ), αy(1 − d
z(t)
z0
) and
βy, respectively. The PSA level v (ng ml
−1) is deﬁned as
v(t) = c1 · x(t) + c2 · y(t).
The transitions between two modes depends on the val-
ues of v, dv/dt and an auxiliary variable w, which measures
the time taken in a mode. Speciﬁcally, for each patient we
starts with mode 1 to apply the treatment. When the PSA
level drops to certain threshold r0 or w hits time out thresh-
old tmax, the treatment will be suspended. When the PSA
228
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Figure 2.2: A simplified hybrid automata example for prostate cancer hormone therapy
by Liu et al. [2]
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2.3.3 Hybrid Petri nets
Formal Definition
A Hybrid Petri net Q is a tuple,
Q = (P, T, h, pre, post, M0)
where:
• Places are represented by P = {P1, P2, . . . , Pn}
• Transitions are represented by T = {T1, T2, . . . , Tn}
• h: P ∪ T → {D,C} indicates the discrete or continuous status for each place or
transition. A non-negative integer is always associated with a discrete place (h(Pi) =
D) , it is called as the number of token. A non-negative real number is always
associated with a continuous place (h(Pi) = C), it is called as the mark
• Pre(Pi, T j)(Post(Pi, T j)) is a function that defines an arc from a place Pi to a
transition Tj, where an arc has a non-negative integer (non-negative real number)as
weight if h(Pi) = D(h(Pi) = C).
Pre and Post functions have the following criterion: if Pi and Tj are a place and a
transition such that Pi is discrete and Tj is continuous then Pre(Pi, Tj) = Post(Pi, Tj)
must be verified;
• M0 is called as initial marking of Petri net as it maps the set of places to the set of
non-negative integers or the set of non-negative real numbers.
Example: Gene operon
An operon is a functioning unit of genomic DNA containing a cluster of genes under the
control of a single promoter. Matsuno et al., described the hybrid Petri net for an operon
containing only two genes. The figure [3] shows the Petri net for operon of two genes
transcription and then translation process.
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Figure 2.3: 2-Gene operon hybrid Petri net model by Matsuno et al. [3]
The figure explains the transcription and translation of two genes, gene 1 and gene 2
in an operon in which:
• Discrete places are: S1, F1, and S2.
• Continuous places are: R1, P1, R2, and P2.
• Discrete transitions are: TR1, T12, and TR2.
• Continuous transitions are: TP1, DR1, DP1, TP2, DR2, and DP2
In the initial marking, the discrete place S1 has a token (this reflects that RNA poly-
merase binds to the promoter of the operon), whereas the marks of other places are zero.
A variable dTj is assigned to manage the delay time of Tj to each discrete transition
Tj(h(Tj) = D) and for the continuous transition Tj(h(Tj) = C), another variable vTj is
assigned for the speed of Tj.
The time required for the transcription of RNA polymerase of the gene1 is the delay
time, which is represented as dTR1, associated with the discrete transition TR1. The place
S1 gets a token and then the transition TR1 is fired after time dTR1. After the transcription
of gene1 the mark of continuous place R1 which represent the concentration of mRNA of
gene1 is increased by Post(R1,TR1). The degradation rate of concentrations of mRNA of
gene1 is given by Pre(R1, DR1)vDR1. The speed vTP1 of the continuous transition TP1 is
the speed of translation of gene1. The place R1 is simultaneously an input and an output
of the transition TP1, because it is required for translation but should not be consumed.
The increasing rate of the concentration of protein of the gene1 is given by Post(P1, TP1)
vTP1. The degradation rate of concentration of protein of gene1 is given by Pre(P1, DP1)
vDP1 . The delay time dT12 of the transition T12 represents the time needed for RNA
polymerase moving between the end of gene1 and the beginning of gene2. At the moment
when the place S2 gets a token, RNA polymerase begins the transcription of gene2. The
same process is repeated for gene 2.
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Hybrid Petri nets (HPN) to hybrid automata (HA)
The hybrid Petri nets and hybrid automata are the formalisms which can be considered
as substitute for each other. They both have significant similarities with each other and
because of this resemblance in representation they both can be interchanged by the choice
of modeler. A hybrid Petri net can be easily converted into hybrid automata. In order to
explain this relationship, the above explained example of gene operon HPN is converted into
HA. In order to develop hybrid automata from the gene operon HPN, all the discrete places
in HPN are represented as states or locations of HA. Similarly, the discrete transitions
are represented as jump statements for the transition from one state to other. All other
continuous processes in HPN including continuous places and transitions are first converted
in to continuous equations, which are represented by real valued variables.
Continuous processes in HPN are converted to continuous equations in HA. The trans-
lation process of a gene is represented as a continuous process in above mentioned HPN.
There are three reactions going on in the process of translation of single gene. The actual
reactions which are taking place in this process can be described as:
R1
VDR1−−−→  (2.1)
R1
VTP1−−−→ R1P1 (2.2)
P1
VDP1−−−→  (2.3)
These reactions simply describe the chemical process going on in gene translation pro-
cess. The R1 is either degraded by VDR1 or it produces product R1P1 by the rate of VTP1.
The product P1 can also be self degraded as represented in equation 3.
Similar reactions are taking place in gene 2.
R2
VDR2−−−→  (2.4)
R2
VTP2−−−→ R2P2 (2.5)
P2
VDP2−−−→  (2.6)
These reactions can be represented as in the form of differential equations. Two equa-
tions can be developed for each gene e.g. for gene1 the equations are R1 and P1 e.g.
dR1
dt
= −R1 VDR1 (2.7)
dP1
dt
= R1 VDR1 − P1VDP1 (2.8)
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Similarly for second gene, the equations will be:
dR2
dt
= −R2 VDR2 (2.9)
dP2
dt
= R2VDR2 − P2VDP2 (2.10)
The initial state of the hybrid automaton is the state where RNA polymerase binds to
the promoter of the operon and the gene translation begins after the delay time of dTR1,
which is the time required for the transcription of gene 1. So, the transition to the state
one starts when t >= dTR1. The states of the resulting hybrid automata are two, first
state in which only gene one is activated and the second state in which gene 1 and gene 2
both are activated, named as State 1 and State 2. In the state 1 the continuous variables
of gene 1 are executed and in the state 2 the continuous variables of both of the genes are
executed. The transition between both states takes place when t >= dT12 + dTR2. The
resulting hybrid automaton is shown in figure 2.4.
R˙1 = −R1VDR1
P˙1 = R1VDR1 − P1VDP1
T >= dTR1 ;
R˙1 = −R1VDR1
P˙1 = R1VDR1 − P1VDP1
R˙2 = −R2VDR2
P˙2 = R2VDR2 − P2VDP2
;
(t ≥ dT12 + dTR2)
1
Figure 2.4: 2-Gene operon hybrid Automata model
Hybrid Petri nets (HPN) vs hybrid automata (HA)
The concept of hybrid Petri nets is not new as it was first introduced by Bail et al. in
1991 [113]. The basic idea is the same as to integrate and evaluate the discrete and
continuous processes altogether in a single model. Various biochemical processes has been
studied utilizing HPN e.g. Troncale et al.[114], proposed a HPN model for the modeling of
Haematopoiesis, which is a complex phenomenon for the generation of all types of mature
blood cells. The mature blood cell population arises from haematopoitic stem cells (HSC).
The haematopoitic stem cell can either goes to a self renewal phase or they can mature into
blood cells, this fate of HSC is defined by interleukin-6 (IL-6), cytokines. The sub-cellular
phase in which HSC convert to mature blood cells is described as discrete switch of states.
While the processes which govern the switch between these states are continuous in nature
and IL-6 activation at molecular state during a continuous process triggers the switch from
one state to another. The analysis of discrete and continuous phases of haematopoiesis
offers deep understanding of the phenomena. Continuous processes in this work are not
described as differential equations which are normally considered as standard representation
of continuous processes in biochemical pathways but instead by exploiting the features of
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continuous Petri nets, by continuous firing of transitions at a rate v(t). The resulting model
is made up of classic Petri nets, initially described for discrete events, and continuous Petri
nets.
Keeping in account the above example for the application of hybrid Petri nets in biol-
ogy, it persuades system biologists to work with this type of formalism with advantage of
capturing concurrency and parallelism inherent in biological processes. But the continuous
processes in biological processes are not so easy to be handled by continuous Petri nets, as
the number of variables to deal with becomes enormously high in various processes. The
cancer progression is an example of such processes and that is why it is easier to model
cancer related processes by differential equations. David Gilbert and Monika Heiner [115]
were the first one to realize the necessity of incorporating differential equations into the
Petri nets to model biochemical processes. In this paper they have first developed a discrete
Petri net model and then converted it into a continuous Petri net in step wise manner. The
resulting model is developed in a way that the continuous model preserves the structure
of the discrete model developed at initial step. They explained there continuous Petri net
model as structured description of ODEs. Although this approach seems to give a solution
to the problem of incorporating differential equations but they have proved their work by
a very small example. It is clearly understood that the proposed extension in the Petri
net formalism can work but for the simple and small case studies. More complex the ex-
ample becomes the more difficult it will be to handle the resulting Petri net model and
the graphical illustration. For big examples of Petri nets will become complicated for the
modeler.
Petri nets are sometimes defined as umbrella formalism for qualitative, stochastic and
continuous models. To easily move between these paradigms the models can be converted
into each other e.g. from discrete Petri net to continuous Petri nets, as in above example.
Snoopy is a tool to handle all of such processes together [116]. This tool is very efficient
in modeling and integrates stochastic and continuous Petri nets functionality to develop a
generalized hybrid Petri net. These hybrid Petri nets are specifically developed for models
in which stochastic and continuous behaviors require an inter-play. The application of
this generalized hybrid Petri net,is useful to model the biochemical reactions which are
composed by two types of reactions, slow and fast reactions for stochastic and continuous
transitions, simultaneously [117]. Overall, the work on hybrid Petri nets by utilizing dif-
ferential equations is not only recent but very less explored for the complex biochemical
reactions with enormous number of continuous variables. So, for modeling complex cancer
problems it is required to explore some other formalism for the ease and accuracy.
Hybrid automaton is a largely explored formalism for all types of hybrid processes in-
cluding biological phenomena. The hybrid automata have an edge over hybrid Petri nets
by having greater power of analysis. The reduced analysis power of Petri nets as compared
to hybrid automata is often tried to overcome by coupling it with hybrid automata [118].
The hybrid automata are widely considered for modeling cellular processes or biochem-
ical processes [119, 120]. The cancer development is a complicated biochemical process
and the hybrid automata has showed promising solution to model almost every aspect of
cancer progression and differentiation. Lots of cancer hybrid automata models have been
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developed to solve different issues regarding identification, observation and solution of the
problem. The basic cancer progression models are developed by differential equations and
automata can easily incorporate differential equations of even very complex nature. Few
examples of such cancer models are briefly described below:
Patel et al.[121] proposed a hybrid cancer model for the evaluation of tumor growth and
the increased anaerobic tumor metabolism. The glucose concentration around the tumor
or uptake by the tumor is represented in the form of differential equations. Similarly,
Gerlee et al.[122], has proposed a cancer model for estimating the impact of cellular micro-
environment on the tumor growth. The impact of tissue oxygen concentration is specifically
observed on the clonal expansion on the tumor. Ribba et al.[97], has also emphasized on
the importance of hybrid cancer model by providing a framework for the improvement of
cancer therapy. The cancer drugs are administered on discrete steps and their effect is
observed on cancer cells.
The above examples convince for the use of hybrid automata in exploration of cancer
research questions. As the all previous mathematical models are originally developed in
differential equations that is why it is easier to develop new models based on previous
ones, so that new arising issues in cancer research can be addressed efficiently. The hybrid
automata are good way to model such biological questions.
In this work the formalism used for modelling is the hybrid automata because of two
main reasons. Main reason is the complex biological nature of the problems aimed to be
studied and analyzed in this research. Cancer is said to be very complicated biological
process with complex intertwined biochemical processes. Although, the hybrid Petri nets
for such type of problems can be developed but the resulting model of such processes shows
very complex graphical illustration which makes it very difficult for the modeler to handle
and analyze. Second, important reason is that, this work is related to clinical practices
performed for cancer treatment. It directly aids the physicians in therapeutic process
and the physicians are more familiarized with automata as compared to Petri net models
because of their generalized and easy way of representation.
Chapter 3
Hybrid Modeling of Colorectal Can-
cer Drug Resistance Mechanism
3.1 Introduction
The World Health Organization (WHO) declared colorectal cancer (CRC) as the second
most common cause of cancer mortality in Europe [123]. The epidermal growth factor,
commonly known as EGFR, has been the focus of main attention in the therapy of col-
orectal cancer as almost all of the colorectal tumors have mutations in EGFR gene. The
specifically designed drugs for targeted therapy in colorectal tumors are called as anti-
EGFR drugs because they target only EGFR mutations. Monoclonal antibody (moAb)
drug has been introduced as the most promising treatment to fight against colorectal can-
cer disease by directly targeting the EGFR. This kind of therapy is more favored then
chemotherapy because of its targeted nature. The chemotherapy has a big drawback of in-
ability to differentiate between tumor and normal cells. This limitation is overcome by the
introduction of targeted therapy such as anti-EGFR therapy in case of colorectal cancer.
Targeted anti-EGFR treatment promises to increase the therapeutic index of disease along
with the maximization of the benefits of drugs and reducing of toxicity. The efficacy of
moAb treatment in colorectal tumors is challenged by KRAS mutations. The development
of acquired resistance to the moAb drug, due to KRAS mutations, makes the problem very
complex in terms of personalized treatment.
In current work, the role of KRAS mutations is critically analyzed in case of moAb
targeting EGFR in metastatic colorectal cancers. In order to do so,a system of non-linear
ordinary differential equations (ODEs)is developed to model the impact of KRAS mutations
on the moAb and chemotherapy combination treatment of colorectal cancer. The behavior
of moAb and chemotherapy is studied with respect to patient immune responses and moAb
drug is also explored as a potential candidate for first-line therapy of CRC, in combination
with chemotherapeutic drug.
The considered treatment pattern of colorectal tumors includes the moAb along with
the chemotherapy. The drugs are administered according to different schedules on discrete
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time steps e.g. moAb is administered bi-weekly while the chemotherapy is given weekly.
The therapeutic procedure is modeled by a hybrid modeling approach in which the effect
of drugs on tumor is analyzed as a continuous function, while, drugs are administered as a
discretely.
The proposed hybrid model for colorectal cancer comprise of two units, the mathemat-
ical model for evaluating the role of mutations on tumor growth due to therapy and the
drug scheduling unit which delivers drug on discrete intervals of time.
EGFR signaling pathway
The epidermal growth factor receptor (HER) is a network composed by four components:
EGFR also known as HER1 or erbB1, erbB2 also known as HER2, erbB3 also called as
HER3, and erb4 or HER4. ErbB receptors are glycoproteins composed of an extracellu-
lar ligand-binding domain, a transmembrane region, and an intracellular protein tyrosine
kinase domain with a regulatory carboxyl terminal segment. This whole pathway is respon-
sible for generating signals crucial for the survival of cell. The mutation in any component
of this network leads towards carcinogenesis.
EGFR is basically a receptor on cell membrane, when its ligand binds to it a signaling
pathway is activated. The ligand for EGFR is EGF, which is an epidermal growth factor.
EGF-EGFR makes a dimer and upon the formation of dimer the intrinsic protein tyro-
sine kinase autophosphorylation is triggered. This autophosphorylation further triggers
cascades of signaling processes. One of the important EGFR downstream pathway is the
RAS − RAF mitogen activated protein kinase (MAPK) pathway. The second important
network activated due to EGFR signaling is the phosphatidylinositol 3-kinase (PI3K)/Akt
pathway. Both of EGFR triggered signalling networks are crucial for various key impor-
tant cellular activities including DNA repair, cell survival and proliferation, differentiation,
motility, adhesion etc.
Due to the critical role of EGFR in cellular processes, it is most widely studied for the
involvement in tumor growth and progression, angiogenesis, invasion and metastasis, and
inhibition of apoptosis. Approximately 90% of colorectal tumors have EGFR mutations.
So, the EGFR targeted therapies are introduced to treat colorectal tumors [124].
Monoclonal antibodies targeting EGFR in CRC
In the case of CRC, two antibodies are approved for treatment of metastatic disease, ce-
tuximab and panitumumab [124]. The highly recommended, most effective and advanced
anti-EGFR drug is the cetuximab. cetuximab is IgG1 monoclonal antibody directed to
the EGFR. It has higher binding affinity when it attaches with extracellular domain of
the human EGFR. This removes the dimers on EGFR and blocks the downstream sig-
naling pathway. Cetuximab antitumor activity includes, cell cycle inhibition, favoring of
apoptosis, anti-angiogenesis and the production of immunological response by enhancing
antibody-dependent cellular cytotoxicity (ADCC). This high performance makes cetux-
imab antitumor efficacy greater than other drugs for colorectal tumors. The treatment of
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cetuximab in combination with either chemotherapy or radiotherapy is more effective for
eradicating metastatic tumors.
Panitumumab is second recently approved drug for colorectal tumor therapy. It is
human IgG2 monoclonal antibody directed to the EGFR. It binds with high affinity to
EGFR and blocks binding of epidermal growth factor and transcription growth factor α.
It inhibits tumor cell activation and induces apoptosis of tumor cells.
Colorectal cancer therapy and KRAS mutations
Monoclonal antibodies are a major breakthrough in CRC therapeutic research because of
their anti-EGFR activity [125, 126]. The Food and Drug Administration (FDA) approved
moAb drugs for colorectal cancer including cetuximab and panitumumab. These drugs
produce promising results when administered in combination with chemotherapeutic drugs
[127, 128]. They kill tumor cells in three ways: by directly blocking the EGFR pathway,
by enhancing the activity of chemotherapeutic drugs and by enabling antibody-dependent
cellular cytotoxicity (ADCC) from natural killer cells.
The most relevant hypothesis concerning the CRC progression during the moAb therapy
is the selection of the treatment of KRAS mutated cells. In particular, it is retained
that there is a small fraction of KRAS mutated cells into the majority of wild-type CRC
cells, that will be selected by the moAb therapy while they will not be killed from the
treatment and they will survive, given treatment acquired resistance [129, 130]. It has been
frequently reported that patients having KRAS mutations show no significant response to
moAb treatment [131, 132]. KRAS mutations are found in approximately 35%-45% of
CRCs [133, 134, 135]. For this reason KRAS mutational status is considered as predictive
marker for determining the efficacy of anti-EGFR therapies, and KRAS screening tests
are prescribed by physicians before the start of treatments [136]. Only patients having
wild type KRAS are eligible for moAb therapy [137]. Interestingly, some patients who
have initially only KRAS wild type cells before treatment, still remain irresponsive to the
medication because of the emergence of KRAS mutations.
Previous models
Various colorectal cancer mathematical models have been developed for basic tumor cell
populations, cell proliferation and for the more complex pharmacodynamic and pharma-
cokinetics in colorectal cancer treatment [138]. These include models of colon crypts
[139, 140, 141, 142, 143] and models of chemotherapy for colorectal cancer [144, 145].
Recently, DePillis et al. proposed a model which includes both chemotherapy and im-
munotherapy along with considerations of patient specific immunity parameters. This is a
comprehensive model which includes tumor cell and immune cell populations, chemother-
apy and monoclonal antibody treatment. Results show the effect of drugs on chemorefrac-
tory tumors [146].
The hypothesis of drug resistance of KRAS mutations in colorectal cancer is quite re-
cent. Diaz Jr. et al. recently published a paper in which they proved that pre-existed small
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number of KRAS mutated cells are responsible for developing resistance to panitumumab
[147]. Another very recent paper by Stites describes a mathematical model which evalu-
ates how different KRAS mutated polymorphisms show different sensitivity to the EGFR
inhibitors [148].
3.2 Hybrid modeling of colorectal cancer
The hybrid model for colorectal cancer is developed to monitor tumor growth with respect
to KRAS mutational status during and after the moAb therapy. In the model, tumor is
evaluated on the basis of KRAS wild-type or KRAS mutated status. The mutated KRAS
tumor subpopulation is resistant to the moAb and chemotherapy but wild-type KRAS
population responds to both of the therapies. It is essential to keep in mind that all of the
tumor population is EGFR mutated as well and further categorization of EGFR mutated
tumor is done on the basis of KRAS mutated or wild-type tumor cells. Tumor grows in
continuous fashion in the presence of the therapies and the drugs are introduced at different
intervals depending upon the standard drug schedules. The hybrid automata is developed
in order to study the dynamic behavior of tumors, the effect of drugs on tumor growth and
appearance of resistance to the drugs in the presence of KRAS mutated cells.
Hybrid automaton for CRC therapy
The colorectal tumor hybrid automata is represented a single state S, which represent a
tumor state.
The state S is governed by a variety of continuous variables. There are three major
types of continuous variables in tumor state S. The tumor variables, the variables for
therapies, and the clocks.
• The continuous variables for tumor include; Tw and Tm describing two type of tumor
populations, the tumor cells with witld-type KRAS Tw and tumor population with
mutated KRAS Tm. The therapy is only effective on wild-type KRAS cells, so, drugs
M and A are only active on wild-type tumor cell population.
• The continuous variables for therapy are M and A representing each drug given to
the colorectal patients. The M represent the chemotherapy drug, while A represent
moAb drug. The concentration of both of the drugs are maintained into the system
by specific decay rates calculated in the respective equations.
• Two clocks C1 and C2 are added into the hybrid automata each clock is associate
with each drug. They monitor the scheduling or timing of administration of each
drug.
The detailed mathematical model with all tumor, immune system and therapy equa-
tions is provided in section 3.3. The equations of tumor mentioned in the hybrid model
representation are incomplete and just provided only to give an idea of tumor progression
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and effects of two drugs on KRAS wild-type tumor. The other continuous variables describ-
ing the representation of immune system components in tumor state are not mentioned
here just to make model simple to understand.
The FDA approved drug schedule for M , which is a chemotherapy drug (irinotecan)
in our model, is the weekly introduction to a system with dose = κ. This means that
M is introduced after every 7 days. Similarly, The FDA approved drug schedule for A ,
which is a moAb drug (cetuximab)in our model, is bi-weekly introduction to a system with
dose = ξ. This means that A is introduced after every 14 days.
The Inv, invariant conditions for the state S are (C1 < 7) or (C2 < 14)
The Init or initial conditions for M and A are κ and ξ respectively. The clocks are are
also initialized by zero, C1 := 0 and C1 := 0.
The jump conditions are associated with clocks, (C1 = 7) or (C2 = 14) The transition
within the state S takes place when any of the two jump conditions (C1 = 7) or (C2 = 14)
is satisfied.
The edges in the hybrid automata are labeled as ((C1 = 7), (M = M+κ), (C1 := 0)) and
((C2 = 7), (A = A+ ξ), (C2 := 0)). In which (C1 = 7) and (C2 = 14) are guard conditions,
(M = M + κ) and (A = A + ξ) are the Act or actions performed when the guards are
satisfied and then both of clocks are reset to zero again by (C1 := 0) and (C2 := 0).
T˙w = aTw(1− b(Tw+Tm))−MTw −ATw
˙Tm = aTm(1− b(Tw + Tm))
M˙ = −γM
A˙ = −ηA
C˙1 = 1
C˙2 = 1
(C1 < 7) & (C2 < 14)
start C1 = 7 , M :=M + κ , C1 := 0
C2 = 14 , A := A+ ξ , C2 := 0
1
Figure 3.1: Colorectal Tumor Hybrid Automata
The resulted hybrid automata gives the drug introduction for M and A at discrete
steps. The modeling of treatment pharmacodynamics as flow condition is shown in the
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figure. 3.2. Where, the M is introduced after every 7 days while, M is introduced after
every 14 days.
Figure 3.2: Colorectal Tumor Therapy Control
3.3 Mathematical model
The proposed mathematical model for colorectal cancer is an extensive model which not
only captures the tumor growth with drug dynamics but it also models the drug resistance
and the probability of the relapse of cancer. Current model is an advanced model for
colorectal cancer and it is based upon previously proposed model of colorectal tumor.
Although, there are various mathematical models for examining the tumor progression
mechanism in colorectal tumors, some models also take into account the therapies but an
interesting and extensive recently proposed model is by DePillis [146]. Current model is
mostly based upon the model by DePillis. In this section, firstly, the mathematical model
by DePillis is briefly described and then extension to this model is proposed after that.
3.3.1 DePillis’ model for colorectal cancer
DePillis et al. [146] has recently proposed a mathematical model for colorectal tumors and
the effect of monoclonal antibody treatments on tumor growth. They have explore the pos-
sible dosing schedules for moAb drugs to obtain maximum promising results for colorectal
cancer therapy. A system of nonlinear ordinary differential equations (ODE) was proposed
to model colorectal cancer growth and treatment. The model by DePillis et al., is a very
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extensive tumor model because it includes not only the tumor cell population and the effect
of drug on tumor but it also takes into account the host immune response. The considera-
tion of immune strength of a patient in colorectal tumor model is very significant because
moAb therapy is actually an immunotherapy and the response of other immune system
components provide good insight into the actual tumor progression process. The modeled
immune system components are; natural killer cells (NK), CD8+ T-Cells, lymphocytes and
interleukins. The model also includes two type of treatment equations; chemotherapy and
moAb therapy by two moAb drugs; cetuximab and panitumumab.
There are basically three main treatment action pathways followed by the moAb drugs
which result in tumor growth rate reduction, complement activation, and possibly other
mechanisms for tumor death. The model captures all these interaction pathways for the
activity of moAb therapy:
• Interactions between moAb drugs, natural killer cells, and tumor cells. These inter-
actions result in invoking the antibody-dependent cellular cytotoxicity (ADCC) from
NK cells thus increases the NK cells cytotoxicity.
• Interactions between moAbs, chemotherapy and tumor cells. The moAb therapy
along with chemotherapy is proven to be associated in the improvement of chemo-
toxicity. The effectiveness of chemotherapy increase when it is administered alon
with the moAb drugs.
• Interactions between moAbs and tumor cells. The moAb drugs are very effective in
directly killing of egfr mutated colorectal tumor cells.
The proposed model tracks the following populations and quantities:
• Cell Populations
– T(w) the KRAS wild-type tumor cell sub-population;
– T(m) the KRAS mutated tumor cell sub-population;
– N(t) the concentration of NK cells per liter of blood (cells/L);
– L(t) the concentration of cytotoxic T lymphocytes (CD8 +) per liter of blood
(cells/L);
– C(t) the concentration of lymphocytes per liter of blood, not including NK cells
and active CD8+T cells (cells/L).
• Medications and Cytokines
– M(t) the concentration of chemotherapy per liter of blood (mg/L);
– I(t) the concentration of interleukin per liter of blood (IU/liter);
– A(t) the concentration of monoclonal antibodies per liter of blood (mg/liter);
The specific explored treatments are the chemotherapeutic drug irinotecan , and
moAbs cetuximab or panatumumab.
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The model incorporates patient-specific parameters to account for individual variations
in immune system strength and in medication efficacy against the tumor. The simulations
are performed on groups of virtual patients using a range of biologically reasonable patient-
specific parameter values. The parameter for the models are derived from available clinical
trial data. The model was evaluated for multiple dosing schedules and the new most
effective treatment schedules are proposed for significant reduction in tumor size. It was
also found that tumor growth is most dependent upon the drug specific pharmacokinetic
and pharmacodynamic parameters.
3.3.2 Extending dePillis’ model
The purpose of this mathematical model is to monitor tumor growth with respect to KRAS
mutational status during and after the moAb therapy. The model is an extension of the
model developed by DePillis et al. [146] by representing tumor cell populations using two
equations, Eq(3.1) for tumor cells with wild type KRAS and Eq(3.2) for mutant KRAS
tumor cells. All the other equations for natural killer cells (NK), cytotoxic T lymphocytes
(CTL), lymphocytes excluding NK cells and CTLs and medications are as in the original
model by DePillis et al. [146]. The model is implemented using the octave programming
environment [149]. For detailed information about the parameter values of the model see
the Appendix. The model includes equations for:
1. wild type tumor cell (Tw) and mutant tumor cell (Tm) populations;
2. patient immune system including, Natural killer cells (N), CD8+ T-Cells (L), Lym-
phocytes (C) and Interleukins (I);
3. chemotherapy (M) and monoclonal antibody (A) treatment;
4. patient immune strength (D).
3.4 Proposed ODE model
The four groups of equations are described below in detail
3.4.1 Equations for tumor cells
Equation for KRAS wild-type tumor cells
Tumor cells with KRAS wild-type nature go through natural clonal expansion process to
form a tumor mass. The only two factors that interrupt the logistic growth of tumor cells
are immune system and therapy. This fact is modeled in Eq. (3.1).
dTw
dt
= aTw(1− b(Tw + Tm))− (c+ ξ A
h1 + A
)NTw
−DTw − (Kt +KatA) Tw
αTm + Tw
(1− e−δTM)Tw − ψATw
(3.1)
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Logistic tumor growth is modeled by term aTw(1 − b(Tw + Tm)). The innate immune
system of the body fights tumor cells with the help of natural killer cells (term −cNTw)
and CD8+ T cells (term −DTw). Two other ways by which tumor cells experience death
are chemotherapy (term Kt Tw
αTm+Tw (1 − e−δTM)Tw) and monoclonal antibody treatment.
The triple action of monoclonal antibody, which is valid only for KRAS wild-type tumor
cells, includes terms for:
• direct killing (−ψATw);
• killing by enhancement of chemotherapy (KatA TwαTm+Tw (1− e−δTM)Tw);
• killing by assisting natural killer cells (−ξ A
h1+ANTw).
Equation for KRAS mutant tumor cells
KRAS mutant cells behave differently from the KRAS wild-types by disturbing the triple
action behavior of monoclonal antibody treatment. The monoclonal antibody is not able
to directly kill KRAS mutant tumor cells and also fails to create chemosensitization in
KRAS mutants. This fact is modeled in Eq. (3.2).
dTm
dt
= aTm(1− b(Tw + Tm))− (c+ ξ A
h1 + A
)NTm
−DTm − (Kt Tw
αTm + Tw
)(1− e−δTM)Tm
(3.2)
Thus Eq(3.2) is obtained from Eq(3.1) by removing the two terms for moAb induced
tumor death in KRAS wild-type tumor cell equation and moAb-induced tumor death by
enhancing activity of chemotherapy.
Both of the equations for tumor contain the terms which describe the interaction of
moAb therapy with natural killer cells or chemotherapy and their effect on tumor growth.
The enhancement of natural killer cells activity induced by moAb therapy is the same for
both mutated and wild-type cells. This is represented in both equations by the −ξ A
h1+ANTw
term. Chemotherapy has reduced effectiveness against tumor cells during monoclonal anti-
body treatment because of mutant cells. This is represented in the model by −Kt Tw
α(Tm)+Tw .
The chemotherapy effectiveness decreases with the increase of the number of mutated cells.
This term is introduced in both the equations of wild-type and mutant tumour cells for
controlling the rate of chemotherapy induced tumor death. Kt is the maximum rate of
chemotherapy induced tumor death in the absence of KRAS mutant cells. The above term
makes the effectiveness of the chemotherapy dependent on the ratio of wild-type and total
tumor cells. This ratio is controlled by the parameter α in such a way that, by increasing
α, the rate of chemotherapy induced death is decreased with respect to the increase in the
mutant population. Similarly, by increasing the initial number of KRAS mutated cells or
by decreasing the initial number of KRAS wild-type cells, the rate of chemotherapy induced
tumor death becomes much lower. Hence, the function clearly models the phenomenon of
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chemotherapy ineffectiveness, in conjunction with monoclonal antibody treatment, in case
of presence of KRAS mutant cells.
Determining accurate α is the key task for producing realistic results. α not only
modulates the ratio of wild-type VS mutated cells but it also depicts the influence of
mutated cells on wild-type cells in making them resistant to the chemotherapy as well.
KRAS mutated cells has the ability to render the neighboring wild-type cells insensitive to
the chemotherapy and the α determines the range of mutated cell microenvironment.
3.4.2 Equations for immune response
Natural killer cells, CD8+ T-Cells, other lymphocytes, and interleukins all play a vital role
in creating immediate immune response with the initiation of tumor. Thus, in order to
analyze the effect of immune system response and strength on the tumor proliferation the
four equations are described. one for each component of immune system.
Natural killer cells
Natural Killer (NK) cells are a fundamental part of host first-line defense system. Their
activity is modeled in Eq. (3.3).
dN
dt
= eC − fN − (p+ pa A
h1 + A
)N(Tw + Tm) +
pnNI
gn + I
−Kn(1− e−δNM)N
(3.3)
They are produced from circulating lymphocytes (term eC) and their activity is stim-
ulated by interleukins (term pnNI
gn+I ). NK turnover is modeled by term fN . In case of
tumor cells NK cells exhibit a special killing mechanism known as Antibody-dependent
cell-mediated cytotoxicity (ADCC). In this process NK cells recognize tumor cells by spe-
cial receptors that identify attached antibodies on the surface of tumor cells. After recog-
nition, NK cells release some cytotoxic granules into the tumor cell which consequently
cause death. The cytotoxic granules are actually tumor killing resources of NK cell; in
case of exhaustion of these resources the NK cells die (term (p+ pa Ah1+A)N(Tw + Tm)). In
addition, NK cells may die due to chemotherapy toxicity (term −Kn(1− e−δNm)N).
CD8+ T-cells
Cytotoxic lymphocytes are part of cell-mediated immunity. They kill target cells by re-
leasing into them specialized granules that program them to undergo apoptosis. They are
vital for killing tumor cells. Their activity is modeled in Eq. (3.4).
dL
dt
= θmL
θ + I + j
Tw + Tm
k + (Tw + Tm)
L− qL(Tw + Tm) + (r1N + r2C)
(Tw + Tm)− uL
2CI
κ+ I −Kl(1− e
−δLM)L+ piLI
gi + I
(3.4)
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CD8+ T cell turnover is modeled by term θmL
θ+I and the breakdown of their surplus in
presence of of IL-2 is modeled by term uL
2CI
κ+I . CD8+ T cells activity is stimulated by
dead tumor cells, lysed by themselves (term j Tw+Tm
k+(Tw+Tm)L), NK cells (term r1N(Tw + Tm))
or the general lymphocyte population (term r2C(Tw + Tm)). Interleukins also perform
stimulating effect on CD8+ T cells (term piLI
gi+I ). CD8+ T cell may die because of exhaustion
of these tumor killing resources (term qL(Tw+Tm)) or due to chemotherapy toxicity (term
Kl(1− e−δLM)L).
Lymphocytes
Lymphocyte count is the most important parameter to be considered while modeling tu-
mors undergoing chemotherapy. Chemotherapy kills normal cells along with the tumor
cells; hence, patients are constantly checked for their lymphocyte count during treatment.
Reduction in lymphocyte count means weakening of immune system, which makes the
body more vulnerable. Lymphocyte activity is modeled in Eq. (3.5).
dC
dt
= α− βC −Kc(1− e−δCM)C (3.5)
Lymphocytes are synthesized in the bone marrow (term α) and their turnover is mod-
eled by term βC. In addition, lymphocytes may be killed by chemotherapeutic drugs (term
Kc(1− e−δCM)C).
Interleukins
Interleukin-2 is a major regulatory factor of immune responses. It belongs to a immune sig-
naling group of cytokines. Interleukin-2 work as an immune response system by increasing
the activity of cytotoxic T-cells. Their activity is modeled in Eq. (3.6).
dI
dt
= −µI + φC + ωLI
ς + I (3.6)
Interleukin-2 is produced in response to activated CD8+ T-cells (term ωLI
ς+I ) or by naive
CD8+T cells and CD4+T cells in the body (φC). Its turnover is modeled by term −µI.
3.4.3 Equations for treatments
In order to monitor treatments, separate equations are defined for chemotherapy (irinote-
can) and monoclonal antibody (cetuximab) Eq. (3.7) and Eq. (3.8), respectively.
Chemotherapy/irinotecan
The activity of chemotherapy depends on the concentration of drug present in body at a
specific time. This can be understood by the rate of excretion of drug from body, which is
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modeled by term −γM . Chemotherapy using irinotecan is modeled by Eq. (3.7)
dM
dt
= −γM (3.7)
Monoclonal Antibody/cetuximab
Monoclonal antibodies bind to the epidermal growth factor receptors (EGFRs) present
on the surface of tumor cells. As an average cell contains thousands of EGFRs, many
molecules of moAb drug are consumed in a single tumor cell. The loss of moAb molecules
due to their binding with the tumor (term λ(Tw + Tm) Ah2+A) is an important factor to be
considered while modeling moAb drug treatment to tumor. The rate of excretion of drug
from body is modeled by term −ηA.
dA
dt
= −ηA− λ(Tw + Tm) A
h2 + A
(3.8)
3.4.4 Patient immune strength formula
Immune strength, i.e. the effectiveness of CD8+ T-cells, is calculated using Eq. (3.9). The
formula uses the lymphocyte count L and total tumor mass Tw + Tm along with other
parameters to compute immune strength.
D = d (L/(Tw + Tm))
l
s+ (L/(Tw + Tm))l
(3.9)
Immune strength D is calculated by considering the following parameters:
d = immune strength coefficient;
l = immune-system strength scaling coefficient;
s = value of ratio (L/(Tw + Tm))l necessary for half maximal CD8+ T-cell
effectiveness against tumor.
(It tells how quickly CD8+ T-cells respond to the presence of tumor.)
In our simulation the parameters are varied to generate three types of immune strength
values: strong, moderate and weak.
3.4.5 Initial conditions and drug dosages
The initial conditions for the model are taken from DePillis model except the number
of KRAS mutated cells. The initial number of KRAS mutated cells, which can cause
resistance to the treatment, is not available in the literature. Thus, a small number for
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KRAS mutated cells is assumed , say 35, because even such a small number of mutated
cells is able to cause resistance. The initial conditions for the model are as follows.
Tw = 4.65928× 109
Tm = 35
N = 9× 107
L = 1.8× 105
C = 9× 108
M = 0
I = 1173
A = 0
The parameter values in our model are also taken from DePilis except the rate of
chemotherapy induced tumor death, which is reduced to the minimum level because of
KRAS mutations. As DePillis, it is assumed that patients are already gone through first-
line chemotherapy and are refractory to the treatment. Therefore, the initial tumor is
assumed to have a very large number of cells: 4.65928 × 109. If tumor size becomes
less than 27 cells during the treatment, it is assumed that the tumor is showing complete
response to the therapy. Similarly, tumors which remain larger then 27 but do not continue
to grow during the treatment are considered to have partial response.
Treatment comprised individual or combination of monoclonal antibody and chemother-
apeutic drug, cetuximab and irniotecan, respectively. The drugs are administered according
to standard FDA approved dosages and timings. For irinotecan, a 125mg/m2 dose is given
over 90 minutes once a week, for 4 weeks. For cetuximab, a loading dose of 400mg/m2
is administered for two hours, followed by a 250mg/m2 dose over 60 minutes given every
week for one month.
The implementation details of resulted hybrid automata are provided in chapter 5.
3.5 Results
3.5.1 Monoclonal antibody effect on chemotherapy
As described before, the effectiveness of chemotherapy against tumor cells gradually reduce
during monoclonal antibody therapy due to KRAS mutated cells. This gradual ineffective-
ness with the increase of mutated cells is modulated by term α in the model. All of the
possible values for α are explored, ranging from 10 to 109. Initially, very low range of α is
explore but in that case, obtained results contradict with the reported experimental data.
The α value is then raised up to α = 106 or α = 107 to get the actual results (Figures 3.3
and 3.4). The reason for this much high α is that a single KRAS mutated cell has the
tendency to influence thousands of wild-type cells.
The results are also analyzed by varying α values along with the varying initial number
of mutated cells. Lower the α greater is the impact of chemotherapy but with the increase
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in number of mutated cell this effect is not much significant. But with lower α and small
number of mutated cells the drug has profound effect, which is not an actual phenomenon.
In reality, chemotherapy also tend to become ineffective with the passage of time.
In the simulations the value α = 107 is used because this shows a gradual decrease in
the efficiency of the chemotherapy as compared to a too rapid reduction experimented with
the smaller value α = 106.
Figure 3.3: α value: 106 shows rapid de-
crease in wild-type and increase in mu-
tant KRAS cells (Red: mutant; Blue:
wildtype)
Figure 3.4: α: 107 shows gradual de-
crease in wild-type and increase in mu-
tant KRAS cells (Red: mutant; Blue:
wildtype)
3.5.2 Treatment trial simulations for KRAS mutated colorectal
cancer tumors
Our model has been evaluated for standard treatments by chemotherapy and monoclonal
antibodies for tumors with KRAS mutations. The KRAS mutated tumors are treated
according to standard dosage of drugs and are evaluated for both monotherapy and com-
bination therapy.
Cetuximab and irinotecan monotherapy
In accordance with the literature, in our model cetuximab monotherapy has no impact
on colorectal tumors because of the number of elevated KRAS mutated tumor cells (Fig-
ure 3.6). Similarly, irinotecan monotherapy has no impact on the tumor because of the
chemorefractory status of tumor. Here, no increase in KRAS mutated cells is noticed
(Figure 3.5). Results show that, although both drugs fail as monotherapies, failure of
cetuximab is specifically caused by an increase in the number of KRAS mutated cells.
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Figure 3.5: Irinotecan monother-
apy(Red: mutant; Blue: wildtype)
Figure 3.6: Cetuximab monother-
apy(Red: mutant; Blue: wildtype)
Cetuximab and irinotecan combination therapy
For patients presenting metastatic colorectal cancer, cetuximab and irinotecan are recom-
mended in combination. The model is used to test the combination of the two drugs.
This allowed to understand the impact of combined therapy on KRAS mutated tumor
cells (Figure 3.7). KRAS mutated cells grow with the passage of time and KRAS wild
type cells start to reduce. However, as the initial number of KRAS mutated cells is very
small, their increase is not clearly visible in the figure. Anyway, even this very low level
of KRAS mutated cells is still able to gradually reduce the activity of drugs (Figure 3.7).
The combination therapy is only effective for KRAS wild-type tumours (Figure 3.8).
Figure 3.7: Cetuximab and irinotecan
as combination therapy with KRAS
mutant (Red: Mutant; Blue: Wildtype)
Figure 3.8: Cetuximab and irinotecan
as combination therapy without KRAS
mutant (Red: Mutant; Blue: Wildtype)
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3.5.3 Patient responses to the therapy
The model is simulated for patients with different immune strengths. Generally, it is
believed that a strong immune system both helps the medication and facilitates quick
recovery, while patients with weak immunity do not respond well to the medicine. The the
interaction between patient immune strength and treatment is analyzed in case of mutation
development during and after medication. The hypothetical immune strength values are
calculated for generating weak, moderate and strong immune responses. These values are
generated by the formula for immune strength (Eq. (??)) by changing the values of its
parameters.
Table 3.1: Cetuximab and irinotecan combination therapy
With KRAS Mutation Without KRAS mutation
Strong Immunity NR/PR (Fig. 3.9) CR (Fig. 3.10)
Moderate Immunity NR (Fig. 3.11) PR (Fig. 3.12)
Weak Immunity NR (Fig. 3.13) NR (Fig. 3.14)
Results are summarized in Table 3.1. Patients without KRAS mutations have complete
response (CR), partial response (PR) and no response (NR) for strong, moderate and weak
immunity, respectively. With KRAS mutations the immune strength has no significant
impact on the treatment. KRAS mutated tumours normally show no response to the
treatment but sometimes there is a partial response in presence of a high immune strength.
For moderate and weak immunity there is no response at all.
Figure 3.9: Strong immunity response
with KRAS mutation
Figure 3.10: Strong immunity response
without KRAS mutation
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Figure 3.11: Moderate immunity re-
sponse to KRAS mutation
Figure 3.12: Moderate immunity re-
sponse without KRAS mutation
Figure 3.13: Weak immunity response
with KRAS mutation
Figure 3.14: Weak immunity response
without KRAS mutation
3.5.4 Cetuximab and irinotecan as first-line therapy
In this section the possibility of using cetuximab and irinotecan as first-line therapy is
explored. Initial conditions are the same as shown in Section 3.4.5.
Patients having weak immunity do not show any significant response to the cetuximab
and irinotecan as first-line therapy (Fig. 3.15). Tumor size reduces significantly in pa-
tients with moderate immunity, but the number of KRAS mutated cells show a relevant
increase (Figure 3.16). The response to the therapy is only observed in patients with strong
immunity and very low number of initial KRAS mutated cells (Fig. 3.17).
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Figure 3.15: Cetuximab and irinotecan
as first-line therapy: weak immune re-
sponse (Red: Mutant; Blue: Wildtype)
Figure 3.16: Cetuximab and irinote-
can as first-line therapy: moderate
immune response (Red: Mutant; blue:
Wildtype)
Figure 3.17: Cetuximab and irinotecan
as first-line therapy: strong immune
response (Red:Mutant; Blue:Wildtype)
3.6 Discussion
Emergence of KRAS mutated status is an alarming situation for colorectal cancer patients
being treated with anti-EGFRs. Presence of KRAS mutations in a tumor treated with
monoclonal antibodies is a sign of becoming refractory to treatments. In order to under-
stand the phenomenon of developing resistance to the anti-EGFRs a mathematical model
is developed with separate equations for KRAS mutant and wild-type cells.
KRAS mutations are considered as driver of resistance to anti-EGFR therapy in col-
orectal cancer. Subset of KRAS wild-type cells in colorectal tumor initially responds very
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effectively to the anti-EGFR drugs but the presence of traces of KRAS mutations prior to
treatment ultimately results in the development of acquired resistance to the drug. Hence,
the treatment of colorectal tumor with anti-EGFRs is only recommended when the KRAS
mutation status is zero. The anti-EGFR treatments to colorectal tumors containing minute
quantity of KRAS mutated cells consequently develop resistance to the therapy. The pre-
existing subclones of mutated cells multiply very rapidly during the treatment and on the
other hand KRAS wild-type cells reduce significantly in their number due to efficient tar-
geting procedure of monoclonal antibody drugs. Eventually, tumor mass repopulate with
the mutated cells and makes tumor much more refractory to other treatments as well. So,
the initial drop in the number of wild-type cells does not contribute much in shrinking
the overall size of the tumor after the treatment. Diaz et al. was the first to discover the
presence of small number of KRAS mutated cells in circulating tumor DNA at very early
stage of drug treatment. This indicates that ostensibly looking KRAS wild-type tumors
hide inside some fatal KRAS mutated cells as well. The mathematical model by Diaz et al.
suggests that circulating DNA analysis for KRAS mutation detection can act as a marker
for early detection of relapse of disease [147]. Misale et al., also confirmed the Diaz et al.
results by in vitro analysis and declared that the reason for development of resistance is
the pre-existence of clones of KRAS mutated cells [150].
A major problem in colorectal cancer is to identify the behavior of monoclonal anti-
body therapy in presence of KRAS mutations and the impact of the mutations on other
therapies. More specifically, exploring the sensitivity of monoclonal antibody drugs to
the chemotherapy and natural killer cells activity in the presence of mutations is another
key issue in understanding drug efficacy [151]. It is speculated in our model that in case
of natural killer cells, cetuximab has equal enhancing effect on both KRAS mutant and
wild-type cells. In other words, KRAS mutational status has no significant impact on the
antibody-dependent cellular cytotoxicity (ADCC) mediated by the drug [152].
The anti-EGFR drugs along with chemotherapy give promising results for colorectal
tumors with wild-type KRAS. Monoclonal antibody is not only a perfect EGFR blocker
but it also boosts the activity of chemotherapeutic drug molecules and results in enhance-
ment of overall antitumor activity [153, 154, 155, 156, 157, 158]. Hence, the monoclonal
antibody therapy in combination with chemotherapy is proved to be effective in avoiding
relapses and increasing the progression free survival period in colorectal cancer patients.
The presence of KRAS mutation in colorectal tumor leaves this combination therapy with
no profound effects on tumor size this means that the chemosensitization operation of
moAb drugs does not imply on KRAS mutated tumor cells [159]. The wild-type KRAS
tumors have longer progression free survival as compared to mutated KRAS tumors when
treated with combination therapy [160, 161, 162, 163, 164]. This reduced survival period
due to mutated KRAS cells is also confirmed in our experiments. The ineffectiveness of
both cetuximab and irinotecan drugs increases with increase in number of mutated cells as
these drugs only influence the wild-type cells. Cetuximab has been frequently reported to
increase chemotherapeutic activity upon combination with irinotecan drug in tumor cells
[165, 156]. Studies show that KRAS mutant cells do not allow cetuximab to produce such
type of chemosensitization [166, 167]. Chemotherapy is effective only at very early stage
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of treatment when KRAS mutated cells are significantly lower in numbers but when the
number of mutated cells in the tumor start to increase the sensitivity of chemotherapy
reduces gradually. In the initial phase of treatment with combination therapy the drugs
seem to reduce tumor a little but soon it goes back to the much bigger and drug refractory
state. Time tumor takes to go back in to maximum or more resistant state is the time
between the relapse which is significantly lower in case of KRAS mutations.
Our results repeatedly confirmed that small number of mutated cells can have an influ-
ence on whole tumor for making it refractory to the therapies. The major point to ponder
is that how a very small proportion of mutated cells make the drug insensitive even to the
wild-type cells. The moAb drug effectiveness on the wild-type cells is well explained but
understanding the change in behavior of wild-type cells because of growing number of mu-
tated cells during treatment is a challenging task for the researchers. BL Parsons and MB
Myers explained this myth of KRAS wild-type cells behavior by blaming KRAS mutant
cells responsible for every unexplained resistance mechanism of the tumor. The mutated
cells undergo negative selection process in poly clonal tumors. Parson and Myers suggested
KRAS mutations as transdriver mutations, these are the mutations which are able to speed
up the tumor progression process even if they are in small proportion[168, 169].
The possible reasons for strong influence of small number of mutated cells on wild-
type cells for producing phenomenal resistance against anti-EGFR drugs lies in tumor
heterogeneity and in the theory of cancer stem cells. Tumor heterogeneity is the reason for
failure of chemotherapy induced tumor cell death, not only for mutated cells but also for
wild-type cells when treated along with the moAb drug[170, 171, 172]. In order to model
this phenomenon the rate of chemotherapy was regulated for induced tumor death. It is
assumed that the effect of chemotherapy decrease with the increase in KRAS mutated cells.
Therefore, one cannot take any benefit from the chemosensitization activity of moAb drugs
in case of KRAS mutations. The chemotherapy may work effectively only at the beginning
of the treatment but then, with the increase of KRAS mutant population, it starts to loose
its strength. Tumor heterogeneity explains the dispersal of mutated cells in the tumor
mass. These distributed resistant cells have strong impact on their microenvironment[173].
They perform like small radiators emitting some harmful radiations which affect a range of
surrounding cells, leaving them resistant to the therapies irrespective of their original wild-
type status. Hobor et al., reported that wild-type KRAS cells has the ability to grow during
the cetuximab treatment when KRAS mutated cells are present in the tumor. Resistant
mutated cells maintain micro-environment inside tumor by influencing their neighboring
cells rendering drug sensitive wild-type cells to resistant cells. The KRAS mutated cells
secrete increased amount of ligands that has the ability to protect wild-type cells from
EGFR blockade by cetuximab drug. The secretion of TGF α and amphiregulin by moAb
resistant KRAS mutated cells sustain the EGFR signaling in wild-type cells too [174].
Tumor heterogeneity is also the major reason for the failure of initial KRAS mutation
screening test. The incorrect assignment of wild-type status to the tumor is because of
widely dispersed mutated cells inside the tumor. The test is only applied to a small chunk
of tumor and there is a chance that the block selected for test may not contain KRAS
mutation and hence give wrong result [175, 171]
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Tumor heterogeneity role in therapeutic resistance is irrefutable but the root cause
of heterogeneity development is the cancer stem cells (CSCs) [176, 177]. CSCs are best
described as the cells having selective advantage of proliferation over the other cells in the
tumor. They occur as minority in tumor and tend to have self renewing property that drive
tumorigenesis [178, 179, 180, 181]. CSCs are rare cells with potential of being naturally
resistant to chemotherapy. The area of CSC research is still underdeveloped that is why
there is no concrete description about the process of chemotherapeutic drug resistance due
to CSCs. If KRAS mutations are considered as CSC then failure of chemotherapy in our
results is justified. KRAS mutated cells are recently been explored as potential CSCs in
colorectal tumors. Evidences support the hypotheses of KRAS mutated cells as CSCs,
which gives us enough explanation about the acquired resistance in colorectal tumor due
to KRAS mutations [182, 183].
Patient immune responses play a vital role in oncotherapeutic processes and this role
varies from positive to negative with strong to weak immune strength respectively. The
immune strength becomes unimportant for KRAS mutated patients because the initially
strong immunity turns into a weak one due to the development of secondary KRAS muta-
tions during the treatment [184]. Even with the highest immune strength, the response to
the drugs is only partial (sometimes). In our simulations tumor size was set to its maxi-
mum and it is considered refractory to the chemotherapy given as first-line to the patients.
The reason for adopting these criteria is because cetuximab is generally given as third- or
fourth-line treatment to the patients as final rescue [185, 186]. Hence it is proved that there
is no correlation between immune strength and combination treatment for KRAS mutated
patients.
The cetuximab and irinotecan combination therapy is proved to be very effective as first-
line therapy for colorectal cancer but this is true only for KRAS wild-type patients [187,
135]. Although KRAS screening tests are always performed before starting monoclonal
antibody treatments, there is a risk of minimal quantities of KRAS mutated cells that
are not detected by common sequencing processes of laboratories. In this case critical
questions arise about the patient response to cetuximab and irinotecan as first-line therapy.
Our results show complete response only in patients with strong immunity. High immune
strength means little number of KRAS mutations, so there is a chance that the drug kills
wild-type cells quickly and chemotherapy also gets the chance to kill mutant cells. The
first-line therapy seems to work also for moderately immune persons but, at the same
time, increases the KRAS mutation level, which is a sign of recurrence of disease. Patient
responses are also dependent upon the initial KRAS mutant cell concentrations. If the
initial mutant level is very low then a complete response can be obtained. However, in
case of greater level of initial KRAS mutants, the response is only partial with decrease
in tumor size and significant increase in KRAS mutant levels, which doubles the chances
of relapse. The relapse after cetuximab as first-line therapy will be more lethal because of
acquired resistance to the drugs due to increased KRAS mutant populations.
In conclusion, the cetuximab and irinotecan combination therapy shows the rapid in-
crease in levels of KRAS mutations and the partial or no response on the tumor size is an
indications of the development of resistance to the drugs. Patients with stronger immunity
48 CHAPTER 3. COLORECTAL CANCER HYBRID MODEL
can be highly recommended cetuximab and irinotecan as first-line therapy but there is no
instrument to accurately judge immunity of a person. Thus there is a potential risk asso-
ciated with standard dosage cycles of drugs. The failure of the treatment will ultimately
lead towards tumor progression with much higher rates. Moreover, the increased number
of KRAS mutations makes the problem even more complex by creating resistance against
the drugs. The co-occurrence of EGFR and KRAS mutations in a colorectal cancer patient
is indeed the worst case scenario.
Chapter 4
Hybrid Modeling of Lung Cancer Drug
Resistance Mechanisms
4.1 Introduction
Lung cancer is the most frequent cause of worldwide cancer mortality, accounting for more
than 1 million deaths per year. Despite therapeutic advances, the overall 5-year survival
remains only 15%. This public health problem is most significant in men. Lung cancer
is of several types but almost 80% of all lung cancer cases are non small cell lung cancer
(NSCLC).
4.1.1 Lung cancer mutations
Non-small-cell lung cancer (NSCLC) is caused by disturbances in epidermal growth factor
receptor EGFR signalling pathway. Multiple mutations occurring in this pathway leads
towards lung cancer. Hence, EGFR signalling is a key network involved in lung cancer
initiation.
EGFR signaling is triggered by the binding of growth factors, such as epidermal growth
factor EGF, resulting in the dimerization of EGFR molecules. Autophosphorylation of the
receptors through their intrinsic tyrosine kinase domains leads to the activation of various
downstream signalling pathways emitting proliferative and cell-survival signals [188, 189,
4, 5, 6]. EGFR signaling plays a key role in promoting the growth and survival of various
types of solid tumors, including non small cell lung cancer (NSCLC) [190, 191, 192, 193].
This ensure the EGFR role as an important therapeutic target.
EGFR is a transmembrane receptor that is expressed on the cell surface in approxi-
mately 80 to 85% of patients with NSCLC. The most commonly found EGFR mutations
in patients with NSCLC are deletions in exon 19 (Ex19del in 45% of patients) and a mu-
tation in exon 21 (L858R in 40 %). Both mutations are commonly known as activating
EGFR mutations and result in activation of the tyrosine kinase domain and are associ-
ated with sensitivity to the small-molecule tyrosine kinase inhibitors (TKIs: eg. erlotinib,
gefitinib). Initial studies with the EGFR tyrosine kinase inhibitors (TKIs) demonstrated
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biological and clinical activity in only a relatively limited subset of lung cancers [194]. Fur-
ther investigation demonstrated that the highest response rates to these TKIs were seen
in patients with somatic mutations within the EGFR-TK domain, particularly exon 19
deletion, exon 21 L858R, and exon 18 G719X [195]. These mutations occur within EGFR
exons, which encodes a portion of the EGFR kinase domain. Approximately 90 percent
of these mutations are exon 19 deletions or exon 21 L858R point mutations [196]. These
mutations increase the kinase activity of EGFR, leading to hyperactivation of downstream
pro-survival signaling pathways.
Even though lung cancer patients harboring a mutation in the epidermal growth fac-
tor receptor (EGFR) gene exhibit an initial dramatic response to EGFR tyrosine kinase
inhibitors (EGFR-TKIs), acquired resistance is almost inevitable after a progression-free
period of approximately 10 months. A secondary point mutation that substitutes methio-
nine for threonine at amino acid position 790 (T790M), is a molecular mechanism that
produces a drug-resistant variant of the targeted kinase. The T790M mutation is present
in about half of the lung cancer patients with acquired resistance, and reported to act by
increasing the affinity of the receptor to adenosine triphosphate, relative to its affinity to
TKIs [197]. Nevertheless, several lines of evidence indicate that the T790M mutation con-
fers growth advantage to cancer cells. The T790M mutation is association with resistance
to TKI therapy and has been reported in approximately 50 percent of patients with disease
progression [198, 199, 200].
Mutations in epidermal growth factor receptor (EGFR)and KRAS mutually are exclu-
sive in patients with NSCLC, and the presence of each mutation can influence response to
targeted therapy. Therefore, these mutations are regularly tested in NSCLC patients in
order to tailor therapy according to genetic profile of a patient [201, 202, 203].
4.1.2 Non-small cell lung cancer (NSCLC) therapy
NSCLC patients were previously treated only with chemotherapy but this treatment has
adverse side effects despite of prolonging the survival time of patients[144]. The use of
cytotoxic chemotherapy is associated with a response rate of 20 to 35 percent and a me-
dian survival time of 10 to 12 months among patients with advanced non small cell lung
cancer[145, 204].
Recently, introduction of tyrosine kinase inhibitors has hugely modified the treatment
of NSCLC. Gefitinib is the most effective tyrosine kinase inhibitor for NSCLC patients.
Gefitinib targets the ATP cleft within the tyrosine kinase epidermal growth factor receptor
(EGFR),[205] which is overexpressed in 40 to 80 percent of non small cell lung cancers
and many other epithelial cancers[206]. Gefitinib is the first agent designed with a known
molecular target to receive FDA approval for the treatment of lung cancer, yet its activity
is limited to a subgroup of patients with non small cell lung cancer. It is effective for the
treatment of all activating EGFR mutations including L858R and Ex19del activating EGFR
mutations. The efficacy of first-line gefitinib was superior to that of standard chemotherapy,
with acceptable toxicity, in patients with advanced non small cell lung cancer harboring
sensitive EGFR mutations [207, 208, 209].
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The positive response of gefitinib is only limited to the activating EGFR mutations.
In this work the included patients are with both type of activating mutations (L858R
and Ex19del), as the activity and effectiveness of gefitinib is almost similar for both type
of activating EGFR mutations. Dramatic responses of gefitinib are observed in NSCLC
patients with activating EGFR mutations.
As gefitinib remains ineffective for EGFR T790M cells, a new drug is introduced for the
treatment trials, AZD9291. 60 % of the patients have experienced tumor shrinkage in recent
trial studies by Pasi and colleagues [210]. This third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) known as AZD9291 showed promising
clinical activity and progression-free survival (PFS). In the simulations, we have virtually
treated geftinib resistant patients with AZD9291 drug and predicted positive results in
almost all of the patients. The positive response observed by AZD9291 drug in geftinib
resistant tumors due to EGFR T790M is not long lasting. Scientists are exploring the role
of KRAS mutations in making tumor resistant to this drug.
Almost all of the NSCLC patients contain EGFR T790M from the beginning but ini-
tially their number is significantly smaller than activating EGFR mutations but with the
passage of time these cells continue to multiply in number hence they render tumor resistant
to the therapy effective for activating EGFR mutations.
4.2 Lung cancer hybrid model
Lung cancer is a complex disease because of appearance of multiple mutations at the same
time and the different behaviors of the mutations towards different therapeutic drugs lead-
ing towards multiple resistant states. Lung tumor at initial stage before application of any
therapy is mostly comprised of activating EGFR mutations. This type of mutations are
treated with an anti-EGFR drug named as gefitinib. After certain level of time gefitinib
therapy starts to loose its strength and tumor shows progression of disease due to appear-
ance resistance towards the therapy. The resistance to gefitinib is because of the growth
of EGFR T790M mutated tumor cells. In other words, the tumor goes from non-resistant
to resistant state when EGFR T790M population becomes greater than all other mutation
populations. This kind of mutated cells are resistant towards gefitinib therapy, so, the
gefitinib administration is stopped at the progression of tumor. In order to treat EGFR
T790M mutated tumor cells another drug named as AZD9291 is prescribed. This drug
treats such kind of mutations very effectively at a certain level of time until tumor again
starts to progress due to triggering of resistance mechanism for AZD9291 drug as well.
The factors of resistant towards AZD9291 are not exactly well understood but most of
cancer scientists believe this to be because of KRAS mutations. At this stage, the tumor
is at so much progressive state that no therapy can be able to completely eradicate it. So,
chemotherapy or other drugs are prescribed at this stage just to prolong the patient life.
The multiple resistant states evoke multiple resistance mechanisms to the drugs.
A hybrid model is developed to understand the evolution of tumor from non-resistant to
resistant state. In this model only one resistant state is considered, which is the resistance
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to gefitinib drug. Second resistant is ignored in this model just because of absence of
sufficient information required for model parameters.
4.2.1 Hybrid automaton for drug resistant state of lung tumor
The lung cancer hybrid automata L is a tuple: L = (L, E, X, Init, Inv, Flow, Jump)
The illustration of lung hybrid automata shown in Figure 4.1
Non − ResistantTumor
T˙ ∗w = a1T
∗
w(1 − bT ) − GT ∗w
˙T ∗m = a2T
∗
m(1 − bT )
˙TT790Mw = a3T
T790M
w (1 − bT )
˙TT790Mm = a4T
T790M
m (1 − bT )
G˙ = −γG
C˙1 = 1
(C1 < 1) & (T ≤ threshold)
start ;
ResistantTumor
T˙ ∗w = a1T
∗
w(1 − bT )
˙T ∗m = a2T
∗
m(1 − bT )
˙TT790Mw = a3T
T790M
w (1 −
bT ) − ST ∗T790Mw
˙TT790Mm = a4T
T790M
m (1 − bT )
S˙ = −βS
C˙2 = 1
(C2 < 1)
;
(T ≥ threshold)
(C1 = 1),(G := G+ ε),(C1 := 0)
(C2 = 1),(S := S + ζ),(C2 := 0)
1
Figure 4.1: Lung Tumor Hybrid Automata
Control states L
The lung cancer hybrid automata L is comprised of two control states of tumor; drug
sensitive state L1 and a drug resistant state L2 ∈ L . The non-resistant and resistant
states of tumor depends upon the level of each mutation comprising a tumor. The lung
tumor hybrid automata is comprised of two control states:
• Non-resistant tumor state L1. This is the initial state of tumor in which tumor is a
collection of multiple mutated cells. The major proportion of the tumor is composed
of activating EGFR mutation, which is sensitive to gefitinib therapy. There very few
cells of other mutated populations and that′s why it is called as non-resistant tumor
state.
• Resistant tumor state L2. This is a state where tumor becomes resistant to gefi-
tinib drug because of reduction of activating EGFR mutation and increase in EGFR
T790M populations.This tumor is resistant to gefitinib drug but sensitive to another
therapeutic drug known as AZD9291.
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Continuous variables (X) Each control state is comprised of following three type of
continuous variables; tumor variables, the variables for therapies, and the clock variable.
1. The continuous variables for tumor include four tumor sub-populations given below.
• Activating EGFR mutated tumor population with wild-type KRAS, represented
by T ∗w in model.
• Activating EGFR and KRAS mutated tumor population, represented by T ∗m in
model.
• Activating EGFR and EGFR T790M mutated tumor population with wildtype
KRAS, represented by T T790Mw in model.
• Activating EGFR, EGFR T790M and KRAS mutated tumor population, rep-
resented by T T790Mm in model.
The gefitinib therapy or drug G is effective on T ∗w tumor sub-population, while, the
AZD9291 therapy or drug S is effective on T T790Mw tumor cells.
2. The continuous variables for therapy are S and G representing each drug given to the
lung cancer patients. The G represent the gefitinib drug, while S represent AZD9291
drug. The concentration of both of the drugs are maintained into the system by
specific decay rates calculated in the respective equations.
The detailed mathematical model with all tumor therapy equations is provided in 4.3.
The equations of tumor mentioned in hybrid model representation are incomplete and
just provided only to give an idea of tumor progression and effects of two drugs on
KRAS wild-type tumor.
3. Two clocks C1 and C2 are added into each state L1 and L2, respectively. Each clock
is associate with each drug. They monitor the scheduling or timing of administration
of each drug. Clock variables C1 and C2 are added to increment the value of each
clock by 1. The clocks takes only two values, initialized by zero, they trigger the
switch state for drug when clock is equal to 1 because the drug is administered on
daily basis.
Each clock monitors the time duration for the drugs. The clock C1 handles the time
schedule for G at state L1 and the clock C2 handles the time schedule for S at state
L2.
Control Switches (E)
There are two types of control switches e ∈ E in the model, where E is the set of edges:
• The first type of switch is from tumor state L1 to L2. This switch depends upon the
tumor size. When the tumor reaches a maximum threshold value, the state of tumor
changes from non-resistant L1 to resistant L2. The threshold value depends upon the
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clinical information data for each patient. The clinical experiments are performed
on regular intervals of time to measure the tumor size and when the tumor starts to
progress again its size is measures and it is considered as threshold tumor size for that
patient. As the growth pattern of tumor varies from patient to patient, the threshold
value also varies. So, the jump condition jump(e) from L1 to L2 is dependent upon
the tumor size. When the jump condition (T >= threshold) is fulfilled, the transition
from non-resistant to resistant tumor state takes place.
• Another type of control switch is the therapy control switch over each state. Both
states L1 and L2 are associated with certain kind of therapy, e.g. the control state L1,
which is the non-resistant tumor state can only be treated by gefitinib drug. The
gefitinib drug is administered on daily basis according to FDA protocols, in order to
introduce drug at daily regular intervals a control switch is added which is associated
with clocks. Similarly, the control state L2, the resistant tumor state, is associated
with another drug, AZD9291. This drug is also administered on daily basis. The
discrete step is evoked for such kind of regular inputs of drugs to the state. The time
of administration is modeled by adding clock here as well. The drugs represented as
G and S are associated with state L1 and L2, respectively.
The Init or initial conditions for G and S are ε and ζ respectively. The clocks are also
initialized by zero, C1 := 0 and C2 := 0. The initial tumor size T0, varies from patient
to patient. Clinical data is generated by wet lab experiments for the initial tumor size
calculation. The jump conditions are associated with clocks, (C1 = 1) or (C2 = 1) and
jump condition for transition from S1 to S2 is dependent on threshold value for tumor
progression, which is T >= Threshold.
4.3 Mathematical Model for Lung Cancer
4.3.1 Equations for Tumor
The model includes four types of tumor equations:
1. Tumor cell populations having Activating EGFR mutation and wild-type KRAS;
2. Tumor cell populations having Activating EGFR mutation and mutated KRAS;
3. Tumor cell populations having Activating EGFR, EGFR T790M mutation and wild-
type KRAS;
4. Tumor cell populations having Activating EGFR, EGFR T790M mutation and mu-
tated KRAS.
All of the tumor sub-populations are essentially activating EGFR mutated as well but
for the simplification purposes in the model only EGFR T790M mutations are mentioned
everywhere.
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Equation for tumor with Activating EGFR and wildtype KRAS (T ∗w)
Tumor cells with Activating EGFR mutation (T ∗) and wildtype KRAS (Tw) are treated
with gefitinib. The only two factors that interrupt the logistic growth of tumor cells are
immune system and therapy. Gefitinib drug is very effective in case of activating EGFR
mutations. This is modeled in Eq. (4.1)
dT ∗w
dt
= a1T ∗w(1− bT )− cIT ∗w − ψGT ∗w − φST ∗w (4.1)
• Logistic tumor growth: a1T ∗w(1 − bT ), here the T refers to overall tumor size by
adding all tumor sub-populations essential to maintain the overall tumor size under
the carrying capacity.
• The immune response: cIT ∗w
• The effect of gefitinib drug: ψGT ∗w
• The effect of AZD9291 drug: φST ∗w
Equation for tumor with Activating EGFR and mutated KRAS (T ∗m)
Tumor cells with Activating EGFR mutation (T ∗) and mutated KRAS (Tm) do not respond
to gefitinib or AZD9291 therapy KRAS mutations. So these tumor cells grow without any
difficulty during the treatment with Gefitnib or AZD9291.
dT ∗m
dt
= a2T ∗m(1− bT )− cIT ∗m (4.2)
• Logistic tumor growth: a2T ∗m(1− bT )
• The immune response: cIT ∗m
Equation for tumor with EGFR T790M and wild-type KRAS (T T790Mw )
Tumor cells with EGFR T790M mutation (T T790M) and wild-type KRAS (Tw) are treated
with AZD9291 as the gefitinib drug is ineffective for EGFR T790M cells.
dT T790Mw
dt
= a3T T790Mw (1− bT )− cIT T790Mw − φST T790Mw (4.3)
• Logistic tumor growth: a3T T790Mw (1− bT )
• The immune response: cIT T790Mw
• The effect of AZD9291 drug: φST T790Mw
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Equation for tumor with EGFR T790M and mutated KRAS (T T790Mm )
Tumor cells with EGFR T790M mutation (T T790M) and mutated KRAS (Tm) are resis-
tant to AZD9291 treatment and that′s why no treatment is effective on the tumors cells
containing both EGFR T790M and KRAS as in Eq. (4.4)
dT T790Mm
dt
= a4T T790Mm (1− bT )− cIT T790Mm (4.4)
• Logistic tumor growth: a4T T790Mm (1− bT )
• The immune response: cIT T790Mm
4.3.2 Equations for therapy
In order to monitor treatments, separate equations are defined for geftinib and AZD9291
drugs, Eq. (4.5) and Eq. (4.6) respectively. In therapy equations the drug decay rates
are represented by the γ and β values for gefitinib (4.5) and AZD9291 (4.6),respectively.
These values are obtained by the formula ln(2)
t 12
, in which, term t12 refers to the half life of
the drug. This formula, based on exponential decay of drug is taken from the DePillis et
al. mathematical model paper for colorectal cancer [146].
Gefitinib
Gefitinib is administered orally on a daily basis. The daily dosage of 250mg gefitnib
administration is maintained in the model as illustrated in the Eq. (4.5). The activity of
drug depends on the concentration of drug present in body at a specific time. This can be
understood by the rate of excretion of drug from body, which is modeled by term −γS in
equation for gefitinib therapy.
dG
dt
= −γG (4.5)
AZD9291
AZD9291 drug is also administered daily like gefitnib but the required dosage is 80mg.
The drug excretion rate is modeled by term −β in Eq. (4.6).
dSG
dt
= −βSG (4.6)
The implementation details of resulted hybrid automata are provided in chapter 5.
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4.4 Materials and methods for clinical experiments
4.4.1 Experimental data
Several kinds of experimental data has been obtained from 7 non small cell lung cancer
patients for model evaluation:
• Tumor size data is obtained by computed tomography scan measurement procedures.
Tumor size is calculated before starting the treatment and then after regular intervals
of 2-3 months to observe the effect of drug on tumor.
• Genetic profile data for each patient obtained by ddPCR of cell free tumor DNA
(cftDNA) or data obtained after biopsy explaining the presence of activating EGFR,
EGFR T790M or KRAS mutations.
• Drug administration schedule data for each patient. Describing the start and stop
dates of drug according to progression time.
The experiments are performed clinically and in the laboratory of pharmacological
unit of University of Pisa, Italy. The data for seven patients is obtained for analysis by
performing various techniques and experiments. The important data acquired for modelling
purposes is summarized in table 4.1.
4.4.2 Clinical experiments for tumor size measurement
Every 2-3 months a CT (computed tomography) scan is performed. Measure of tumor
nodules (primary tumor and the relative metastases) are taken according to RECIST cri-
teria [211, 212]. In this procedure some nodules are chosen according to the physician
judgment and their maximum diameter is measured. The sum of each maximum diameter
of the target nodules gives you an idea how the tumor is changing over time. For example,
comparing the sum of the maximum diameter of a new CT scan with the previous, you will
say that the tumor is in progression (PD) if the sum > 20%, is in partial response (PR)
if the sum is < 30%, is in complete response (CR) if the tumor disappear and is stable
(SD) if the sum 30% < x < 20%. There is an exception if a novel tumor node (metastasis)
compares the tumor is considered in progression (PD).
4.4.3 Tumor cell free DNA experiments for identification of mu-
tations
Plasma collection and cftDNA extraction
Six ml of blood were collected in EDTA and centrifuged at 4◦C for 10 min at 3000 rpm
within two hours after blood drawing. Plasma samples were stored at −80◦C until analysis.
cftDNA was extracted using a QIAmp Circulating nucleic acid Kit (Qiagen, Valencia, CA)
from 1 to 3 ml of plasma following the protocol by manufacturer and the DNA was eluted
in 100 µ l of buffer.
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Analysis of cell free tumor DNA (cftDNA)
The cell free tumor DNA analysis was performed to investigate the contribution of muta-
tions in tumors. The lung tumors are checked for the EGFR and KRAS mutations using
this analysis. This kind of experiment is significant because it can reveal the presence of
mutation even when it is little in amount and also it removes the need for biopsy for find-
ing the mutations in a tumor. This is the reason that, this technique is more reliable and
efficient then other type of simple polymerase chain reaction(PCR) methods. The investi-
gational part of this study was the assessment of KRAS codon 12 and EGFR c.2369C>T
(p.T790M) mutations in cftDNA. Other mutations potentially associated with EGFR-TKI
resistance were not examined because of the limited amount of cftDNA available.
The analysis of cftDNA was performed by digital droplet PCR (ddPCR, BioRad, Her-
cules, CA, USA) and ddPCR Mutation Assay (BioRad). The analytic procedure was
unable to discriminate the nature of the KRAS mutations detected because the analy-
sis was performed with a ddPCR KRAS Multiplex assay. PCR reactions were assembled
into individual wells of a single-use injection molded cartridge, according to the following
protocol:
20 ng of template DNA (4µl), 1µl of 20X target primer/probe assay (FAM), 1µl of
20X wild type primer/probe assay (HEX), 10µl of 2X ddPCR Super Mix and 4 µl of
DNAse/RNAse-free water up to a total volume of 20µl. Droplet generation oil (70µl)
was then loaded and the cartridge was placed into the droplet generator. Using vac-
uum, sample and oil were mixed, generating mono-disperse droplets. Thereafter, 40 µl
of packed droplets were transferred into a 96 well PCR plate for thermal cycling am-
plification. The protocol was standardized for all mutations to the following conditions:
95◦C × 10min, 94◦C × 30sand55◦C × 60s(35cycles), 98◦C × 10min, and4◦C hold. The
droplet reader (BioRad) was used for fluorescence signal quantification. The concordance
between KRAS and c.2369C > T (p.T790M) mutational status was assessed on pairwise
cftDNA and tissue DNA of 8 patients who underwent re-biopsy for diagnostic purposes.
DNA was extracted from formalin-fixed paraffin-embedded biopsies using the QIAmp DNA
Mini Kit (Qiagen) and analyzed using conventional diagnostics as reported above. As a
positive control for mutKRAS, the cftDNA from 30 patients with known KRAS mutated
pancreatic cancer was used, while the DNA extracted from plasma of 43 healthy blood
donors was employed as negative control for KRAS and p.T790M mutations. A 0.1 % and
0.2% cut-off was set for the detection of p.T790M and KRAS mutant alleles, respectively,
as per manufacturers manual[213, 214].
4.5 Results
4.5.1 Wet lab experimental results
Data obtained from wet lab experiments provides three types of information: mutation
status of a patient, gefitinib start and stop dates, tumor size at start of therapy and at
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disease progression. All this information has been summarized in a table 4.1. The data
has been collected from 7 NSCLC patients.
Each patient has activating EGFR mutation with mixed proportion of L858R and
Ex19del activating EGFR mutation type. Gefitninb drug is very effective for both type
of activating EGFR mutations. So, each patient is treated with gefitinib initially after
the diagnosis of NSCLC. Tumor size is calculated at several intervals to check for the
progressive disease. The only one patient among 7 shows complete response to the gefitinib
therapy (patient ID=30) and one patient shows progressive disease at the second month
after initialization of treatment. All others show partial response to the treatment as
the gefitnib drug slowly eliminates the activating EGFR mutations but other mutations
continue to increase in number.
Table 4.1: Lung cancer patient summarized experimental data; PD= Progressive disease,
CR= Complete response, PR= Partial response, Gef= Gefitinib
Patient IDEGFR MutationKRAS status Initial tumor sizeTumor size at PD1Tumor size at PD2PD after Gef start(days)Stop Gef (days)Response
32 Ex19del No 2.7×1011 2.9×1010 1.2×1012 450 450 PR
24 Ex19del yes No data NA NA 803 1235 PR
30 Ex19del No 22.4×1010 NA NA NA 250 CR
20 L858R yes No data NA NA 600 682 PR
29 L858R No 1.574×1011 45.12×1011 NA 550 NA PR
26 L858R yes 8.5×1010 1.8×1011 NA 74 74 PD
27 L858R yes 1.15×1013 4.5×1011 7.5×1011 144 144 PR
4.5.2 Calculating number of cells in tumor
In laboratory experiments tumor size is normally obtained in millimeters. For our simu-
lation experiments we require to describe tumor size in number of cells in a tumor. It is
hard to explain number of cells present in a tumor mass. Scientists believe that 1cm3 of
tumor contains 1 × 109 cells [215, 216]. According to this hypothesis we have calculated
number of tumor cells from tumor size in millimiter. May it is not so much accurate way
to calculate number of cells but it surely provides an estimate for the analysis.
4.5.3 Initial conditions and parameter value for model
Initial values for tumor equations
Initial tumor size is obtained from the real tumor size of the patients calculated by labora-
tory experiment before the start of gefitinib treatment. The initial conditions for the four
tumor populations is dependent upon that real patient data. As we know by literature that
initially lung tumors are mostly comprised of activating EGFR mutations, so the initial
condition for activating EGFR tumor population is almost the same as the original size
of the tumor calculated in the laboratory. We assume that EGFR T790M cells are also
present in the lung tumor but initially they are in very small numbers which varies from
patient to patient. In this model the initial value for EGFR T790M cells is also not fixed
for all patients but it is changed in every patient to obtain the same curves or trend of
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tumor growth as observed in real patients but this value is never set to be greater than 200
cells. KRAS mutated tumor population initial values are dependent upon the detection
of KRAS mutations in tumor by ddPCR laboratory test. If the laboratory test shows the
presence of KRAS cells then the fixed initial values are assigned for all patients having
KRAS positive status, otherwise the KRAS mutated populations are set to be zero. In
case of KRAS positive test the activating EGFR and KRAS population is initiated with
only 35 number of cells, while, EGFR T790M and KRAS population initial value is 15
cells.
Grow rates for tumor populations
The grow rates for activating EGFR mutations is derived from the literature (ref) but for
all of the other mutated populations the values are assumed, as no experimental proof is
available in previous research. In lung cancers the KRAS mutations are multiplied in very
slow motion. They grow very slowly and gradually in numbers in an unnoticed way until
they reach a significant number and makes tumor resistant to almost all of the drugs. The
grow rates for both KRAS mutated populations is set to be very small. The grow rate
of EGFR T790M population is varied in each patient to obtain the same tumor growth
curve as observed in real patients. The grow rate for EGFR T790M for each patient is
summarized in table 4.2. Greater the grow rate more quickly tumor reaches to its resistant
state, similarly, smaller the grow rate greater time tumor takes to reach resistant state. The
grow rate parameter in each tumor equation is named as a1, a2, a3 and a4 for activating,
activating + KRAS, EGFR T790M and EGFR T790M + KRAS populations, respectively.
a1(ActivatingEGFR) = 0.5 (4.7)
a2(ActivatingEGFR +KRAS) = 0.05 (4.8)
a3(EGFRT790M) = variesineverypatient (4.9)
a4(EGFRT790M +KRAS) = 0.05 (4.10)
Table 4.2: EGFR T790M grow rate for tumor samples
Patient ID EGFR T790M Grow Rate
32 0.01
24 0.009
30 0.05
20 0.01
29 0.1
26 0.3
27 0.0
Immune strength parameter
The immune strength represented by term ′cI ′ in all four equations of the tumor. This
immune strength is actually a estimate of natural killer cells activity on tumor cells. It
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is taken as a constant value parameter instead of measuring dynamics of immune cells
response according to therapy. It is because the effect of immune strength on the NSCLC
therapy is not so evident from the literature. In the term ′cI ′, the parameter ′c′ represents
the tumor cell kill rate by natural killer cell and ′I ′ represents the number of natural killer
cells.
4.5.4 Validation of model by experimental results
The mathematical model is verified by producing same results as obtained through experi-
mental techniques. This involved the fine tuning of only two parameters, the initial number
of mutated cells and grow rates for each mutated populations. The overall initial tumor
size was maintained same as calculated by experimental techniques. As the lung tumor
is initially comprised of activating EGFR mutations. So, the initial number of activating
EGFR mutations is set to be highest in the simulations. While, the initial percentage of
EGFR T790M and KRAS mutated cells are set to be very low in order to obtain exact
replica of real patient tumor. The grow rate of activating EGFR mutations is greater as
compared to EGFR T790M so the initial number of both type of mutated cells play a
significant role in overall grow rate of the tumor and this also explains that how quickly a
tumor can reach to its resistant state.The gathered patient experimental data only gives
the result of Gefitnib treatment on patients. We have validated the same effect of Gefitnib
in our simulations and hence developed the exact patient profiles for our model experiments
as real patients studied in laboratory experiments.
Initial size of the tumor is not the only parameter that govern the overall dynamics
of tumor progression. The grow rate of EGFR T790M is also tailored to get the required
growth pattern of the tumors to obtain the results like real patients. The grow rates for
activating EGFR and KRAS mutations are set to be the same for all patients (0.5 for
activating EGFR and 0.05 for KRAS). Different patient profiles generated by only varying
the grow rate for EGFR T790M and initial number of mutated cells. To our surprise, this
produces the virtual patient profiles approximately similar to the real patients.
Patient ID 30
This patient has Ex19del activating EGFR mutation. There is also evidence of EGFR
T790M presence from biopsy data but KRAS status is zero. We set the KRAS population
equal to zero throughout in our simulation for this patient. Patient shows quick and
significant response to the first-line therapy of gefitinib drug without any relapse. The
fast and positive response to the gefitinib therapy is may be because of two reasons; very
small number of initial EGFR T790M mutated cells (30 cells) and negative status of KRAS
mutated cells (fig:4.2). The grow rate of EGFR T790M is set to be 0.05.
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Figure 4.2: Complete Response to Gefitinib Therapy (Patient ID:30)
*The encircled points represent the real data points obtained by lab experiments
Patient ID 26
This patient shows progressive disease just after 2 months of gefitnib therapy start date.
This means that initial number of EGFR T790M is much higher in tumor which makes
tumor resistant to gefitinib at the beginning stage. The figure shows little decrease in tumor
size in the start but this decrease is not so significant and tumor again grow back and shows
progression of disease(fig:4.3). For simulation the initial number of EGFR T790M is set
to be equal to 300, while the grow rate for this mutation is set to be 0.3, which is much
higher but still lower than activating EGFR growth rate of 0.5.
Patient ID 29
This tumor shows partial response to the gefitinib treatment (fig:4.4) but significant com-
plete response to the AZD9291 drug because of absence of KRAS mutations (fig:4.13).
Patient ID 27
This patient′s tumor shows partial response to the gefitinib treatment (fig:4.5.
Patient ID 32
This tumor shows partial response to the gefitinib treatment (fig:4.6)
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Figure 4.3: No response to gefitinib therapy (Patient ID:26)
*The encircled points represent the real data points obtained by lab experiments
Figure 4.4: Partial response to gefitinib therapy (Patient ID:29)
*The encircled points represent the real data points obtained by lab experiments
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Figure 4.5: Partial response to gefitinib therapy (Patient ID:27)
*The encircled points represent the real data points obtained by lab experiments
Figure 4.6: Partial response to gefitinib therapy (Patient ID:32)
*The encircled points represent the real data points obtained by lab experiments
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Patient ID 20
No tumor size data is available for this patient. The tumor growth curves obtained by only
considering the dates of progressive disease and drug start and stop time. This tumor also
shows partial response to the gefitinib treatment (fig:4.7)
Figure 4.7: Partial response to gefitinib therapy (Patient ID:20)
Patient ID 24
This patient has maximum survival period in our selected group of patients even with the
presence of KRAS mutations. In simulations there is only EGFR T790M grow rate who is
responsible for this but in real case study the reason is not clear (fig:4.8)
4.5.5 AZD9291 drug effect on EGFR T790M tumor cells induced
resistance to gefitinib
AZD9291 is a new drug undergoing experimentation by the scientists to be checked for
its clinical usability as second line therapy for NSCLC tumors experiencing EGFR T790
mutations. This drug directly targets EGFR T790M and is very effective to overcome
the gefitinib drug resistance crisis caused by EGFR T790M cells. After the validation
of lung cancer mathematical model parameters, the model is used to monitor the effects
of AZD9291 drug on patients previously treated with Gefitnib. The activity of Gefitnib
drug on tumor cells is determined by obtaining the same tumor growth patterns from the
real clinical data of the patients. So gefitinib induced death rate, referred as ψ in (4.1)is
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Figure 4.8: Partial response to gefitinib therapy (Patient ID:24)
set to be 0.005 for all patients because this value gives perfect curves as observed in real
patients but we do not have any clinical data to assess the activity of AZD9291 drug on our
patients. And also there is no sufficient information available in literature for assessing this
parameter, so, in the simulations we have estimated the rate of AZD9291 induced cell death
by varying the parameter φ in (4.3). Every simulation for testing AZD9291 is performed
for three different φ values (0.05, 0.005 and 0.009)for evaluating the most suitable values
for φ that provides best representation of drug activity for each patient. The best suitable
value is chosen to be
The tumor growth reduction curves obtained with three different values for φ can be
seen in Fig.4.9, 4.10 and 4.11, respectively. The rate of 0.05 kills all tumor cells very quickly
just before 40 days, which is the most unrealistic assumption. The kill rate 0.009 seems to
be little OK as compared to previous 0.05 value but it is still a quick elimination of tumor
within 3 months which is not so acceptable behaviour. Hence, it is evident that 0.005 value
of φ gives more realistic result with moderate kill rate of tumor cells as tumor reaches to
only 10 × 7 size after 100 days. Approximately same growth patterns are observed in all
of the patients with varying φ values and 0.005 value is turned out to be most acceptable
value for our simulations
Patient having complete response from gefitinib
The patient having complete response from gefitinib (Patient ID:30) is excluded from this
analysis.
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Figure 4.9: φ value 0.05 Figure 4.10: φ value 0.009
Figure 4.11: φ value 0.005
68 CHAPTER 4. LUNG CANCER HYBRID MODEL
Patient with progressive disease with gefitinib
The treatment with AZD9291 drug is totally ineffective for progressive disease lung tu-
mor(Patient ID:26). As the number of EGFR T790M cells and the grow rate of this
mutation was set to be very high at the stop time of gefitinib drug, the treatment seems
to fail according to our simulations. Although the appearance of KRAS mutations is also
confirmed through laboratory tests but in simulations the KRAS status is not considered
as the drug is ineffective even without KRAS mutations. The simulated treatment with
AZD9291 drug initially seems to be effective for such type of tumor but the remarkable
increase in KRAS cells shows alarming condition which means that this tumor shrinkage
due to AZD9291 drug is not so long (fig:4.12).
Figure 4.12: Partial response to second-line AZD9291 therapy (Patient ID:26SG)
Patients with partial response to gefitinib without KRAS mutation
The patients having partial responses in previous gefitinib treatment have notable responses
to the AZD9291 drug provided with zero KRAS mutation status (Patient ID:29 and Patient
ID:32).
Patients with partial response to gefitinib and KRAS mutation
Patients who obtained partial response from the gefitinib and also have presence of KRAS
mutation confirmed by experimental ddPCR method also shows the reduction in tumor size
with AZD9291 drug(fig:4.15). If we take into account the contribution of KRAS mutated
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Figure 4.13: Partial response to gefitinib therapy (Patient ID:29)
Figure 4.14: complete response to AZD9291 therapy (Patient ID:32)
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cells to the overall tumor size. It shows that tumor is going towards the ultimate resistant
position, the KRAS resistant state (fig:4.16).
Figure 4.15: Partial response to AZD9291 therapy (Patient ID:27)
4.6 Discussion
Experimental results confirms gefitinib as a very effective TKI drug but only for activating
EGFR mutations[217, 218, 219]. The main reported reason for the resistance to gefitinib
drug is EGFR T790M. According to our results and previously published research, the
appearance of EGFR T790M is inevitable in NSCLC patients. Data obtained from real
patients has been utilized to validate our mathematical model. Parameter tuning for the
model is done by following patient′s clinical evaluation data and also by wet lab tumor
size calculation results. Most important parameter is the grow rate estimation for each
mutation. For our simulations we have only tailored the grow rate for EGFR T790M to
obtain different patient profiles matching with real patient data. Although, there is no
biological explanation for using differed grow rates of EGFR T790M for each patient but
it was necessary to obtain same results as in real patients. It is noticed in our results that
smaller the grow rate of EGFR T790M more time it takes to reach the resistant state.
Further investigation is required to explore the governing factors for the change in grow
rate of mutations from patient to patient. It is a possibility that immune system may have
any impact on preferential growth of the mutations because immune system is reportedly
involved in pathogenicity and progression of lung tumors [220]. The idea of immunoreg-
ulation as lung cancer therapy is recently being explored by researchers [221, 222]. The
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Figure 4.16: Partial response to AZD9291 therapy (Patient ID:27)
modulation of mutation grow rates by immune system can provide key idea towards the
immunotherapy of lung cancer. The verified model parameters allows to further utilize this
model to investigate the effect of other drugs using same patient specific parameters on
NSCLC tumors. In this case the authentication and higher precision of simulated results
is also very much guaranteed.
Recent studies introduce a new drug named AZD9291, with promising results for treat-
ment of EGFR T790M. AZD9291 high activity has been confirmed in a very recent study
conducted by Janne and colleagues [223]. In previous years various other researchers has
also proved that irreversible tyrosine kinase inhibitor activity of AZD9291 has the ability
to overcome the resistance issues due to EGFR T790M [224, 225]. AZD9291 drug ability
of selective targeting of EGFR T790M has proved this drug to be most effective in near
future [226, 227, 228, 229]. This drug has passed few trials for NSCLC patients but still it
is not so commonly used by the physicians. The main reason for this is that this drug is
still going through the trials. In current research we did simulations to study the impact
of AZD9291 on the real patient data treated with gefitinib drug. We collected data for
8 NSCLC patients and produced exactly same results obtained in real patients treated
with gefitinib. Then we continued our simulations to check that if the same patients are
treated with AZD9291 drug then what will be the effect on tumor size. To our surprise, all
of the patients having partial responses with gefitinib drug showed a significant response
to AZD9291 drug. Except one patient (patient ID:26) who have progressive disease sta-
tus after approximately 4 months of the start of treatment with gefitnib drug. Although
this patient also shows a significant reduction in tumor size after starting therapy with
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AZD9291 but at that time the KRAS mutated cells are much higher in numbers that it is
evident that tumor again goes back to more resistant state then before, the KRAS resistant
state.
KRAS mutations seem to have no significant impact on the tumor resistance to gefitinib
drug but it may effect later during AZD9291 activity. Very recent study by Eberlein and his
colleagues pointed out the activation of RAS signalling pathway during AZD9291 treatment
and appearance of resistance for this drug [230]. The possible explanation for this behavior
is that, if the tumor show slower response to these therapies and continue to stay in almost
same state after initial reduction in size then KRAS mutated cells can get a chance to
survive and multiply with the passage of time and become able to produce resistance
against AZD9291 drug. Hence, AZD9291 drug which tends to be an ideal solution for
EGFR T790M merely becomes a life incremental drug by only increasing the life span of
patient because underlying KRAS mutations are so strong by that time that its too late
for any other drug.
In order to avoid tumor to become KRAS resistant, we need to explore the possibility of
treatment of EGFR T790M and KRAS mutations simultaneously. Currently, the practiced
lab tests can only reveal about the presence of certain mutations. If we are able to quantify
the number of mutated cells for all EGFR T790M and KRAS mutations then it would
help in controlling the disease progression towards threshold mortality or death point by
making drug administration choices smartly on quantities of mutated populations. At the
time of appearance of gefitinib resistance the EGFR T790M is much more in quantity
then KRAS so the AZD9291 drug could be the first priority for the treatment of major
resistance mutation but before the start of AZD9291 treatment KRAS status must be
checked specifically by ddPCR for more accuracy. If the patient is KRAS positive then
administer AZD9291 drug very carefully and measure the tumor size on regular basis and
if tumor shows little bit of progression then change the AZD9291 drug with chemotherapy
or any other drug specifically for KRAS mutations.
In conclusion, the lung cancer patients with EGFR T790M can be recommended to
be treated with AZD9291 but only if the patient shows partial response with gefitinib
treatment. The behavior of KRAS mutations in lung cancer treatment with AZD9291
drug is still not clear so there is dire need to observe more closely the behavior of KRAS
mutations for producing resistance towards AZD9291drug.
Chapter 5
Implementation of Hybrid Models
The hybrid models described in this thesis are implemented in Octave version 3.6.1 [149].
Octave is a free GNU program for doing numerical mathematics. It is a high-level language
for numerical computations and it provides a way to find numerical solutions for linear and
non-linear problems. The commands of octave are mostly compatible with Matlab. It also
has graphics capabilities for data manipulation and visualization.
The hybrid models can be implemented in octave as it has several solvers for the solu-
tion of continuous processes e.g. FSOLVE, LSODE etc. The choice of solver depends upon
the nature of problem. Non-linear ordinary differential equations can be solved by LSODE
solver. The function LSODE uses the solver by Hindmarsh for ordinary differential equa-
tions [231] Hybrid models have two parts, continuous and discrete. The implementation
of continuous part is easier in octave but incorporating discrete events during continuous
process is tricky.
Solving the continuous part of a hybrid model
Solving ordinary differential equations in octave requires just a call to the function. The
function LSODE can be used to solve ODEs of the form
dx
dt
= f(x, t); (5.1)
with x(t0) = x0, which is the initial state of the system.
The differential equations can be written as in the form of a vector called xdot. The
coupled differential equations can be solved by representing each equation as xdot(1),
xdot(2), xdot(3),...xdot(n).
LSODE takes three arguments: the function f (x , t) containing differential equations as
xdot, the initial condition for each xdot equation and the time vector t.
In order to understand how LSODE works, let us consider the following small example
of differential equation
dx
dt
= 10; (5.2)
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In octave this equation is represented as xdot vector, xdot(1) = 10;, and it is written
in the function as:
function xdot = f (x , t )
xdot (1)= 10 ;
endfunction
Then in the main file LSODE solver calls this function
x0 = [ 0 ] ;
t = linspace ( 0 , 2 0 ) ;
y =lsode (@ (x , t ) f (x , t ) , x0 , t ) ;
A = ( y ( : , 1 ) ) ;
plot ( t ,A)
This was the simple illustration for solving differential equations by LSODE.
Adding the discrete behavior
Implementing discrete transitions to continuous processes in octave is a bit tricky part.
Simple discrete transitions can be implemented as simple if, else conditions inside the xdot
function. For example in equation
dx
dt
= 10 + Transition(x); (5.3)
where the discrete function transition is
Transition(x) =
 20, if x ≥ 10010, otherwise
The discrete step of this type can be easily implemented in if,else conditions for xdot
equations
function xdot = f (x , t )
i f ( x(1)<100)
xdot (1 ) = 10 ;
else
xdot (1 ) = 20 ;
endif
endfunction
But the problem arises when modeler try to change the value of x(1) by some external
function because LSODE do not allow to change the values of xdot equations. This can be
considered as the limitation of LSODE. So, trying to add discrete events needs to be done
by playing some tricks with the solver and this method can vary according to the modeling
problem.
The implementation of proposed hybrid models for the colorectal and lung cancer case
studies differs on the basis of discrete processes in both case studies.
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Discrete step implementation in colorectal cancer case study
In the first case study of colorectal cancer the discrete event is the administration of two
drugs simultaneously at different time steps, one is administered weekly and other bi-
weekly. The discrete function is added in the equation for both of the drugs as:
dM
dt
= −γM + vM(t) (5.4)
dA
dt
= −ηA− λ(Tw + Tm) A
h2 + A
+ vA(t) (5.5)
In both equations the vM(t) and vA(t) can be described as discrete drug administra-
tion functions, which is the dosage of drug. Adding drug dose is easier but decide when
to administer this dose is difficult because LSODE computes its own time steps for the
computations and adding discrete function at time steps defined by LSODE returns wrong
results. So, in order to define at which time step a discrete step of drug administration
is performed there is the need to define some external function. The external function
which can manage to handle time steps in LSODE is the basic requirement for this. Oc-
tave provides a way for this by tailoring ′train − sigmoidal′ function with discrete steps.
Sigmoid− train function simply evaluates a train of sigmoid functions at t. It takes range,
rc and t. Range determines the number and duration of each sigmoid, rc is an array that
defines the rising and falling time constants of each sigmoid and t is the time vector. This
function can be manipulated to handle the time of discrete events to be performed. Oc-
tave code for using this function and passing the resulting values as external parameters
to LSODE is given below. It simply describes the timing of the discrete events to be
performed.
range= [ 0 0 . 0 5 ; 7 7 . 0 5 ; 1 4 14 . 05 ; 21 2 1 . 0 5 ] ;
r c= [ 0 0 ;0 0 ;0 0 ;0 0 ] ;
s i gmo id t r a in= @ ( t ) s i gmo id t r a in ( t , range , rc ) ;
y = lsode (@ (x , t ) xdot (x , t , s i gmo id t r a in ) , x0 , t ) ;
Inside the xdot function of above drug equations the information from sigmoid− train
function is added as:
xdot (1)= −gamma x (1) + ( s i gmo id t r a in ( t ) )∗ dose1 ;
xdot (2)= −eta x(2)− lambda ∗(Tw+Tm)∗x (2)}/{h2+x (2)} +
( s i gmo id t r a in ( t ) )∗ dose2 ;
Where the dose1 and dose 2 correspond to the administration of dose for drug 1 and
drug 2, respectively.
Discrete step implementation in lung cancer case study
In lung cancer case study the discrete step is also an administration of two drugs but not
simultaneously and is dependent upon the overall size of the tumor. The tumor is initially
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treated with drug1 and when it reaches to certain threshold size then the drug is switched
to drug2. There are again two equations (5.6)(5.7) for two type of drugs but switching
between drug1 and drug2 on the basis of tumor size is the main discrete step. Another
discrete step is same as in the previous model, the drug administration at discrete time
steps and is done in the same way as described before. The equation (5.6) is for gefitinib
drug, the drug administration at regular intervals is maintained with discrete function
vG(t). The equation (5.7)is for the drug AZD9291, here again the drug administration is
maintained by discrete function vSG(t). Both vG(t) and vSG(t)are implemented in the
same way as previous model.
dG
dt
= −γG+ vG(t) (5.6)
dSG
dt
= −βSG+ vSG(t) (5.7)
The switch between therapy is simply done by if, else condition, where T represents
overall tumor size.
i f (T<= thre sho ld )
xdot (1)= −gamma x (1)
else
xdot (2)= −beta x (2)
endif
The proposed hybrid models for the colorectal and lung cancers can also be imple-
mented in some other ways by using Mathematica, Matlab or by R language, but the
octave is chosen for the implementation because of its free availability and having good
numerical computation power. It is very easy to solve differential equations by octave and
the described models containing many complex differential equations. The octave code for
colorectal cancer and lung cancer case studies can be accessed on the links provided at
[232]and [233], respectively.
Chapter 6
Conclusion and Future Work
The hybrid modeling for cancer drug resistance mechanisms can provide a breakthrough
in personalized cancer therapy. The proposed hybrid models for colorectal and lung cancer
very much enlightens about the drug resistance mechanisms specific to these cancers. The
involvement of immune system is very critical in the treatment procedure of cancer and its
role during the therapy is very much highlighted in the development of the models. Fur-
ther extensions to these models may lead towards more efficient and accurate therapeutic
procedures.
In case of colorectal cancer, by utilizing the proposed model, the level of KRAS muta-
tions could be measured, that can be tolerated to avoid resistance to anti-EGFRs. This
could provide information to stop the anti-EGFR treatment before reaching the threshold
value for KRAS mutant cells. The treatment could be switched from anti-EGFR to anti-
KRAS drugs. The clinical perspective about switching treatments is not known, but this
could provide a better way to solve the secondary KRAS mutation problem in colorectal
cancers.
The application of different monoclonal drugs and by varying administration schedules
or dosages for same drugs in colorectal cancer, may also provide a solution for the precise
personalized therapy of colorectal tumors. The further exploration of KRAS mutated cells
fate as cancer stem cells and development of tumor heterogeneity is required. Tumor
heterogeneity makes the problem of resistance against the drugs even worse, as a small
number of mutated cells are able to make drugs ineffective even for a large number of
wild-type cells. The future plan is to further investigate this interplay between wild-type
and mutant cells caused by tumor heterogeneity.
As future work, a stochastic feature can be introduced for KRAS mutations in the
current model in order to increase the accuracy of the model. The current model could
also be upgraded to cellular hybrid automata to observe the behavior of small number
of KRAS mutations in the presence of drug and the impact of minute quantity of these
mutations on surrounding tumor populations. The cellular automata are well known for
modeling the spatial information of tumors. In order to analyze the growth and effect of
KRAS mutated population in colorectal cancer the spatial information for these cells is
essential to consider in a model.
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Similarly, in case of lung cancer, the strict regulations of treatment procedures is re-
quired to avoid the transition of tumor from non-resistant to resistant states. The si-
multaneous or combined treatment of gefitinib and AZD9291 drugs could be checked for
controlling the resistant sub-populations in tolerable proportions.
In order to make the current lung hybrid model more easier for the management of drug
introduction and scheduling in future, it is needed to upgrade this model by parallel com-
position of lung tumor hybrid automata with drug controller hybrid automata. The idea
behind the parallel composition of tumor and drug automata is to make the personalized
treatment of lung tumors easier. In the parallel compositions of the model tumor automata
will be only comprised of tumor sub-populations and drug automata will control the in-
troduction of both of the drugs. The tumor automaton will be composed/sunchronized
with the drug controller via the help of some shared variables. The tumor progression with
increase in multiple sub-populations in separate tumor automata and the parallel drug
controller automaton will help the drug management with respect to the proportions of re-
sistant sub-populations of the tumor. It will become easier to model the effect of any other
drug for the lung tumor by having a drug controller automata independent of tumor growth
automata. The lung tumor heterogeneity can also be observed and managed by introduc-
ing a descriptive automaton linked to tumor state, which can provide the description of
dominant tumor sub-population as the tumor progresses with respect to the therapy. This
tumor heterogeneity information along with tumor progression behavior seems promising
to point out the more effective drug administration procedures for personalized treatments
of lung cancer.
Appendix
Table 6.1: Tumor Equations Parameters
Pa-
rame-
ter
Description Value
a Logistic tumor growth 2.31× 10−1(Day−1)
b Inverse of carrying capacity 2.146 ×
10−10(Cells−1)
c Rate of NK induced tumor death 5.156 ×
10−14(LCells−1Day−1)
ξ Rate of NK induced tumor death
through ADCC
6.5 ×
10−10(LCells−1Day−1)
h1 Concentration of moAbs for half max-
imal increase in ADCC
1.25×10−6(mgL−1)
Kt Rate of chemotherapy induced tumor
death
0 − 8.1 ×
10−1(Day−1)
Kat Additional chemotherapy induced tu-
mor death due to moAbs
4 ×
10−4(Lmg−1Day−1)
δ Medicine efficacy coefficient 2× 10−1(Lmg−1)
ψ Rate of moAb induced tumor death 2.28 ×
10−2(Lmg−1Day−1)
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Table 6.2: NK Cell Equation Parameters
Pa-
rame-
ter
Description Value
e
f
Ratio of NK cell synthesis rate with
turnover rate
1
9
f Rate of NK cell turnover 1× 10−2(Day−1)
p Rate of NK cell death due to tumor
interaction
5.156 ×
10−14(LCells−1Day−1)
pa Rate of NK cell death due to tumor
moAb complex interaction
6.5 ×
10−10(LCells−1Day−1)
pn Rate of IL 2 induced NK cell prolifera-
tion
5.13×10−2(Day−1)
gn Concentration of IL 2 for half maximal
NK cell proliferation
2.5036 ×
105(IUL−1))
Kn Rate of NK depletion from chemother-
apy toxicity
9.048 ×
10−1(Day−1)
δN Chemotherapy toxicity coefficient 2× 10−1(Lmg−1)
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Table 6.3: CD8+ T Cell Equation Parameters
Pa-
ram-
eter
Description Value
θ ConcentrationofIL − 2tohalveCD8 +
T − cellturnover
2.5036 ×
10−3(IUL−1)
m Rate of activated CD8+ T−cell turnover 5× 10−3(Day−1)
j Rate of CD8+ T cell lysed tumor cell
debris activation of CD8+ T cells
1.245 ×
10−4(Day−1)
k Tumor size for half maximal CD8+ T
lysed debris CD8+ T activation
2.019×107(Cells)
q Rate of CD8+ T cell death due to tumor
interaction
5.156 ×
10−17(Cells−1Day−1)
r1 Rate of NK lysed tumor cell debris acti-
vation of CD8 + T cells
5.156 ×
10−12(Cells−1Day−1)
r2 Rate of CD8+ T − cell production from
circulating lymphocytes
1 ×
10−15(Cells−1Day−1)
u CD8+ T − cell self limitation feedback
coefficient
3.1718 ×
10−14(L2Cells−2Day−1)
κ Concentration of IL − 2 to halve magni-
tude of CD8+ T − cell self regulation
2.5036 ×
103(IUL−1)
Kl Rate of CD8+ T − cell depletion from
chemotoxicity
4.524 ×
10−1(Day−1)
δL Chemotherapy toxicity coefficient 2× 10−1(Lmg−1)
pi Rate of IL − 2 induced CD8+ T − cell
activation
2.4036(Day−1)
gi Concentration of IL− 2 for half-maximal
CD8+ T − cell activation
2.5036 ×
103(IUL−1)
82 APPENDIX
Table 6.4: Lymphocyte Equation Parameters
Pa-
rame-
ter
Description Value
α
β
Ratio of rate of circulating lymphocyte pro-
duction to turnover rate
3 ×
109(CellsL−1)
β Rate of lymphocyte turnover 6.3 ×
10−3(Day−1)
Kc Rate of lymphocyte depletion from
chemotherapy toxicity
5.7 ×
10−1(Day−1)
δC Chemotherapy toxicity coefficient 2 ×
10−1(Lmg−1)
Table 6.5: Interleukin Equation Parameters
Pa-
ram-
eter
Description Value
µ Rate of excretion and elimination of IL−
2
11.7427(Day−1)
φ Rate of IL − 2 production from CD4 +
/naive CD8 + T cells
1.788 ×
10−7(IUCells−1Day−1)
ω Rate of IL− 2 production from CD8 + T
cells
7.88 ×
10−2(IUCells−1Day−1)
ς Concentration of IL− 2 for half-maximal
CD8+ T − cell IL− 2 production
2.5036 ×
103(IUL−1)
Table 6.6: Medication Equation Parameters
Pa-
rame-
ter
Description Value
γ Rate of excretion and elimination of
chemotherapy drug
4.077× 10−1(Day−1)
η Rate of moAb turnover and excre-
tion
1.386× 10−1(Day−1)
λ Rate of moAb-tumor cell complex
formation
8.9 ×
10−14(mgCells−1L−1Day−1)
h2 Concentration of moAbs for half-
maximal EGFR binding
4.45× 10−5(mgL−1)
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